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All sites M 784 897 1000 1066
F 942 959 980 961
Lip M 12.8 12.6 11.4 8.1
F 0.8 0.7 0.7 0.7 f
Tongue M 43.1 50.8 45.9 28.5
F 4.4 4.3 3.8 3.5
Oesophagus M 51.2 60.6 64.1 50.8
F 14.6 16.5 18.0 18.4
St omach M 167.2 186.4 220.2 231.6
F 133.0 139.0 154.2 150.5
Intestine M 63.5 96.8 124.8 142.8
F 72.3 109.2 128.5 139.1
Rectum and anus M 79.8 93.6 105.0 113.7
F 55.9 59.3 59.3 59.3
Ovary and F 19.2 24.3 36.1 53.2
Fallopian tube
Uterus F ? 174.4 157.7 126.9
Breast F 158.4 170.8 188.4 197.3
Skin other than M ? 17.6 17.5 17.1
rodent ulcer, F ? 10.9 10.1 10.2
penis, and
scrotum
Larynx M ? 23.9 31.2 28.6
F ? 6.0 7.1 7.1
Lung and bronchus M 10.2 12.7 25.1 115.2
F 7.0 7.0 9.6 26.0
Prostate X. 11.8 26.5 47.3 64.4
Table I. Cancer Mortality. Rates per Million
Population (Standardised) at the more important
sites for selected years. Data abstracted and
rearranged from Table LIX of the Registrar
General's Statistical Review for the Years
1938 and 1939, Text. 1947.
INTRO-DUCT IOff ■
That the treatment of cancer is far from
satisfactory is generally admitted. The public
obviously do not share the enthusiastic claims of
some cancer therapists that great "advances" in the
treatment of cancer have been made in the last 25
years. In Table I is given an extract from the
Statistical Review of England & Wales (Registrar
General 1947) summarising cancer mortality trends
at various sites since 1901, Also given in Table
II are the Comparative Mortality Indices at selected
cancer sites for 1951 and 1941 relative to the base
year 1938, (Registrar General 1953). (The figures
are adjusted for age differences in the populations
exposed to risk.) It can be seen that there has
been no fall in the incidence of deaths from cancer
as an whole. Although at some sites there has been
a fall, notably uterus and skin, this is more than
compensated by a rise at other sites. Yet at some
cancer sites which account for large numbers of
deaths, e.g. breast, rectum, the cure rate after
treatment is claimed to be about 40f. Assuming
that the incidence of cancer at such sites at each
age has remained fairly constant then an appreciable
fall in the death incidence would have been expected























































































Table II. Comparative Mortality Indices (Base Year
1938) at certain cancer sites selected from Table
9 of the Registrar General's Statistical Review of
England and tales for 1951. Adjustment has been
made for age differences in the population exposed
to risk.
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may be inaccurate but they are unlikely to mask an
average curability of cancer of about 25/ if this
were being achieved. Cancer treatment is claimed
to be much more effective than it was twenty years
ago and facilities for early diagnosis and treatment
are much more widespread.
The object of this thesis is to examine the
methods of analysis of the treatment of cancer in
an attempt to explain the apparent discrepancy
between what is claimed for cancer treatment and
what is achieved by cancer treatment.
The thesis will be in seven partes
I. The Difficulties in Evaluating the Value
of Cancer Treatment will be examined. These mainly
arise from the difficulty in diagnosing cancer and
in assessing the degree of malignancy of a known
cancer. Unless there is definition of what is
being cured the results of treatment are largely
indefinite.
II. The Claims for the Curability of Cancer
will be discussed and the conclusion will be reached
that treatment does not "cure" cancer but at the
most prolongs life.
III. The present day Concept of Cancer Behaviour
is criticised as are the conclusions relative to
- 3 -
treatment which, are based on that concept. An
attempt to alter this concept will be made in order
to provide an acceptable basis for analysing the
behaviour of treated or untreated cancer.
IV. An Index or Formula to Summarise Cancer
Behaviour is therefore necessary. The criteria for
evolving an accurate index of cancer behaviour will
be examined.
V. The Present Methods of Analysing Cancer
Behaviour and the Results of Treatment will be
criticised and particularly the fallacies of the
"five year survival rate" as an index.
VI. An Attempt to Evolve an Accurate and
Sensitive Index of C.ancer Behaviour will be made.
This index it is hoped will o\Tereonie as many as
possible of the drawbacks of present methods of
analysis.
VII. Discussion and Summary.
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I. DIFFICULTIES IN THE EVALUATION OF
CANCER TREAT iiBMT .
A, Difficulties in Diagnosis.
1. Lack of a Definition.
The word "cancer •' has a wide range of meanings
Clinically, it may mean a rapidly fatal disease
running its course in a few weeks or a slowly
spreading neoplasm which takes 20 years to kill.
Histologically, it may mean a basal cell tumour of
the skin which may cause no inconvenience if left
for 30 years, or a tumour with a certain pattern
which the diagnostician thinks might (but will not
necessarily), kill the patient in the near future.
This wide range of lesions included in the
term cancer is the root cause of all the difficulties
in assessing the benefits of treatment of cancer.
Mo one knows whether the results of this form of
treatment are better or v/orse than those of that,
because it is rarely that any two treatment clinics
deal with groups containing exactly the same propor¬
tion of patients comparable with respect to age,
degree of malignancy of the cancers, stage of
growth, etc.
2. The Fallibility of Histology.
The surgeon, the layman and the lawyer all
haye great faith, in the part histology plays in the
accurate diagnosis of cancer. Although the surgeon
may subsequently discover that an histological
diagnosis was wrong, he assumes that the histologist
was unskilled and that a "better" histologist would
have given the correct diagnosis and that absolute
truth is achievable. This is not so. The
histological diagnosis of cancer is like any other
medical diagnosis - the result of weighing up of
many and sometimes conflicting probabilities and is
itself merely a statement of probability and not an
assertion of fact. As in all medical diagnosis the
accuracy will very with the skill of the diagnosti¬
cian but will never be absolute.
Diagnosis only Prognosis. At the time the
diagnosis is made the diagnosis of cancer by histo¬
logy is only a prediction of its future behaviour.
It is a prognosis, and as such is fallible.
A lump found accidentally is called cancer
because in the opinion and experience of an histolo¬
gist it shows characteristics which he has learnt to
associate with a subsequently malignant infiltrative
behaviour. But other factors beside the histology
must be taken into account in assessing the
prognosis, such as the age of the patient or the
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site from which the tissue has been removed. For
example, melanomas of the skin or adenomatous polyps
of the rectum occurring in childhood may show the
histological patterns which one associates with
metastaslng malignancy at these sites in the adult.
Yet in both cases simple excision is a safe form of
treatment and in the great majority metastasis does
not and never does occur.
Again, a wedge of tissue removed from the site
of a possible carcinoma of the lung, of the skin of
the vulva.and of the skin of the hand,may all show
an identical histological picture. In the first
case the lesion might be diagnosed as cancer with
confidence and in the second with doubt. In the
third case it might well be given as benign.
Histologically Proven. If a cancer therapist
wishes to boast of the accuracy of his diagnoses he
usually claims that they are "histologically proven",
implying that they possess the absolute accuracy of
a mathematical proof. An histologist's opinion is
based partly on his own experience but largely on
the experience of others reported verbally or in
books. Since no two cancers have the identical
histological pattern and no two histologists have
the same experience nor interpret other men's
experience in the same fashion, "histological
malignancy" is an elastic term. There are lesions
which all men will call cancer and others which all
men will call benign. Between these there is a
zone of patterns which some will call one and some
the other. <
Cancer of the breast is one of the commonest
and easiest cancers to diagnose. let out of the
same hundred cancers diagnosed by one histologist,
another histologis.t will only diagnose 95 and label
the remainder as non-malignant, fibrosing masto-
pathias. In the prostate the debatable zone is
even broader, probably up to 15i> and in the thyroid
might be as high as 50%, Such differences in
standards of diagnosis must make comparisons of
cure rates invalid.
Overdiagnosis. There is a tendency to over-
diagnose cancer and the less skilled the histologist
the greater the tendency. It may require skill and
courage to refuse to diagnose a lesion as malignant.
In case of doubt both the histologist and the sur¬
geon find it easier to call the tumour cancer: the
former to avoid the disgrace of "missing" a cancer
which later recurs contrary to prediction, the latter
because he can now assure the patient (and himself)
that treatment is safe and complete. This tendency
is most obvious in cancers at sites such as the
breast, lip, skin, prostate, colon or even the
rectum where excision of the afflicted area does
not lead to gross mutilation.
Overdiagnosis will also occur nowadays because
doubtful tissue i3 examined more often. Ho lump
is now permitted to remain without biopsy whereas
fifty years ago many doubtful lumps spontaneously
regressed without the benefits of enthusiastic
diagnosis and surgery, and were not claimed as cancer
cures.
"Early" Cancer. This term is usually used by
the histologist as a face-saving formula to get the
best of both worlds. If the tumour recurs he
diagnosed it correctly; if it does not recur then
the surgeon "got it all away". Admittedly there
are leukoplakias, "preaalignant" mastopathies,
"intraepidermal" cancers of the cervix, etc., in
which it is difficult if not Impossible to predict
the probability of subsequent frank malignant infil¬
tration. If these lesions must be called cancer it
is better to call them cancers of a low grade of
malignancy with low metastasising potential, than to
use the word "early" with the meaning that these are
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frank cancers at an early stage of their life.
3. The Nature of Present Cancer Treatment.
The ideas of cancer behaviour generally held
at present and the rigid separation of all tumours
for purposes of treatment into two distinct classes
- benign and malignant - strain the impartiality of
the histologist or therapist in diagnosis. He
must decide immediately whether the lesion is malig¬
nant or not malignant; if malignant, treatment must
be immediate and radical.
Unless metastases appear later there is no
check on the accuracy of the diagnosis and it is
only natural that once the diagnosis of cancer has
been given and acted upon the record is not easily
changed.
B. Difficulty in Assessing Degree of Malignancy.
Even assuming that it is possible to predict
with some degree of accuracy that a particular
tumour will have metastasising power, it is not
possible at present to predict truly the rate of
appearance and the number, or even the site, of any
metastases which might occur if the cancer is
treated or not treated. An estimate of prognosis
in the individual case is highly speculative.
- 10 -
The very variability of cancer behaviour has
forced those who wish to compare the effect of
different treatments to subdivide their cancers
into what they believe to be groups of cancers of
the same degree of malignancy. In these classifi¬
cations there is confusion between the inherent
malignancy of the cancer, i.e. its growth rate, and
the time for which the cancer has been growing.
"Early" might mean a cancer of slow but long growth
and no wide dissemination,or a highly malignant
cancer of short duration which is still localised
clinically but which will shortly disseminate. At
*»
present two common methods of defining malignancy
are histological grading and extent of spread at
diagnosis.
Histological Grading. This is not of great
value in individual prognosis. It is based on
features intrinsic to the tumour pattern, the mitotic
activity, degree of differentiation, cellular
irregularity, etc. It is well recognised that these
vary in different parts of the same tumour and be¬
tween the secondary and the primary. Also there is
little correlation between the factors which are
supposed to indicate degree of malignancy, e.g.
mitotic activity might be intense in a well
- 11 -
differentiated keratinising squamous cell cancer.
Or a widely disseminating sarcoma of the uterus may
show no cellular pleomorphism, while a soft tissue
sarcoma with a wildly irregular cellular picture and
*
intense mitotic activity may never metastasise after
repeated local excisions.
These factors are usually assessed after the
outcome is known when other factors, such as extent
of spread or clinical rate of growth, give a much
"better clue to prognosis, and knowledge of which •
tends to "bias the histological grade into which the
cancer is put.
Extent of Spread Stages. This has so far
proved to be the most reliable guide to malignancy,
that is, to prognosis and curability. The extent
of spread at diagnosis is the result of all the
factors which go to make up malignancy. Of these
the most important are:- (1) The inherent malignancy
of the cancer. (2) The time for which the cancer
has been growing. It is probable that the first of
these is by far the most important and the extent of
spread found at diagnosis is an indication of this
factor.
This method has however its disadvantages.
The number of stages into which the extent of spread
\
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can be divided is limited. For even a crude
estimate the tissue must be available for histologi¬
cal examination and the processing and examination
of multiple areas which might be invaded is
expensive and time-consuming. All cancers do not
spread in the same step-by~step fashion as does the
usual carcinoma of the rectum or the breast.
Although melanocarcinoma commonly occurs in a limb
it does not necessarily involve the lymph nodes of
that limb as a selective route of spread.
Even cancers which have reached the same extent
of spread at the time of diagnosis do not behave
thereafter in a similar fashion. It is not very
rare for a surgeon to excise a breast with its
primary cancer and a large mass of invaded lymph
nodes in the axilla, and for the patient to survive
for at least ten years; whereas a patient with a
small cancer the sise of a pea histologically of
identical pattern with no clinical metastasis, given
the same treatment, dies six months later riddled
with metastases. There is therefore here a wide
variability of behaviour even within the extent of
spread stages.
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C. Difficulties of Evaluating Pure.
1. hat is meant "by cure?
The treatment of cancer is at i>resent "based on
the idea that a malignant tumour grows and spreads
as a result of successive uncontrolled proliferation
of its constituent cells and that it spreads by
direct extension or by emboli to distant sites. By
continued growth at these sites and the replacement
of vital tissues death will ensue.
The object of treatment, it follows, is to kill
or to remove all cancer cells while they are still
within the limits of accessibility. According to
theory sll cancers can be rigidly divided into two
classes:-
1. Those in whom the cancer cells have been
killed or excised. These patients should all be
permanently cured.
2. Those patients from whom the cancer has not
been completely removed. Continued growth at the
metastatic sites should occur and those patients
should die as quickly or nearly as quickly as
patients who had no treatment at all. The only
value of excision of the primary tumour would be to
remove the toxaemia of an ulcerated surface or to
perform an anastomosis of some hollow organ which
would otherwise toe obstructed by the cancer. In
cancers at any site the prolongation of life on the
average would not be great and at sites such as the
breast would be nil.
But treated cancers do not all behave in this
fashion. Outlying cells which have not been
removed may lie dormant for ten, twenty or even
thirty years before the metastatic deposits suddenly
■
appear and death rapidly ensues. It is difficult
to accept that the depression of the activity of the
malignant cells was an inherent property of the cells
themselves.
1
The writer has seen a metastasis the size of a
tangerine orange removed from the left lobe of the
liver at the same operation in which the primary
cancer of the lower colon was removed. The patient
I
is alive eleven years later. It is difficult to
believe that only one embolus of cancer cells was
thrown off to produce a single liver metastasis.
Many others must have occurred; yet none of them
"took" or has taken. Factors in the host must have
played a part in keeping the patient free from
further overt metastases.
Such behaviour which is by no means uncommon is
difficult to fit into the commonly held ideas of
- 15 -
cancer behaviour. The assumption that treatment
plays no part in slowing the rate of growth of the
cancer tissue which remains after inadequate removal
must be false#
Treatment can reasonably be considered to have
one or other of at least three possible effects.
1# It can cure a proportion of cancers' and the
remainder will progress as if they had never been
treated.
2. It can cure some cancers and those patients
not cured may have their lives prolonged.
3. There is no such effect as cure, merely
prolongation of the survival time. This prolonga¬
tion of survival will vary and in some esses the
freedom from recurrence will persist till death
occurs from other causes.
This last seems to be the most probable effect
of treatment and this contention will be developed
later.
2. The Behaviour of Untreated Cancer.
An appreciable proportion of patients diagnosed
as having cancer live for five years after treatment.
The claim for at least the partial curability of
cancer depends on this undoubted fact. It is of
interest and importance to examine if possible the
TABLE III.














Breast 651 38.3 43.33 16#
Uterus 1749 20.9 17.13 3#
Rectum 887 26.7 25.41 5#
Tongue and
Mouth 369 16,5 13.21 2#
Oesophagus 299 12.0 10.76 <2# |
Larynx 129 14.5 11.25 <2#
Stomach 154 16.8 12.58 <3#
Table III. Tiie Natural Duration of Untreated
Cancer from the Time of Onset of Symptoms to
Death*
Data abstracted from Sreenwood 1926.
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behaviour of untreated cancer. If we fix an
arbitrary period such as five years as the time
after which survivors are claimed to be cured, then
even if a few untreated cases survive for this period
it will be correspondingly difficult to assess the
number of true cures.
Greenwood (1926) collected and summarised the
findings of several British authors who had investi¬
gated the period of survival from onset of symptoms
to death,of patients who suffered from cancer but
who received no curative or palliative treatment.
These figures are summarised in Table III. It is
to be noticed:-
1. Those cancer sites at which radiotherapist!
or surgeons claim to be able to ensure an high pro¬
portion of cures are the same sites as those in which
the mean period of survival without treatment Is
appreciable. (It is noteworthy that these are also
the sites at v/hich the surgeon and radiotherapist
are prone to indulge in controversy about the
relative merits of their respective techniques.)
2. In all six cases the mean survival time is
roughly equal to the standard deviation. This
measure of the variability of the values is such that
roughly 2/3 of the values will lie within the limits
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(mean - S.B.) to (mean + S.B.) and about one-sixth
of them will have values greater than, (mean + S.D.).
7/e can therefore postulate that for untreated
cancer, (and it will he shown that the same is true
for treated cancer) the survival times are so
variable that roughly one-sixth of the cases will
have survival times greater than twice the mean
survival time.
(In the tables quoted, time is measured in
simple time units and the distributions are undoubt¬
edly skew. If time is transformed to logarithmic
units the distributions are more symmetrical.
Assuming that the space of time between the point of
diagnosis and the earliest deaths is short, then we
would expect to find that the S.B. of the distribu¬
tion in log.time units is approximately one-third of
the mean time in log. units. This relationship is
in fact found.)
3. It is noteworthy that all the patients of
this series died of cancer. There were no doubtful
"early" cases. why they were not treated is not
stated in the report, but by far the most likely
cause in the majority was that the growths were too
widespread or inaccessible for radical treatment at
the time of diagnosis,or that the patients were
FIGURE I.
TIME
Figure I. life Histories of the Individuals of a
series of Cancers.
To show that a small difference in rate of growth
at the time of diagnosis results in marked
difference in survival time.
•The line D-D runs through the points which
represent the threshold for diagnosing malignancy
in each cancer.
0 * Point of occurrence of irreversible
lalignancy.
s = Appearance of primary cancer,
r = Appearance of first regional metastasis,
g « Appearance of first generalised metastasis.
1 = Extent of spread sufficient to cause death.
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thought not to be fit to undergo the rigours of
treatment. The mean time of survival of all breast
cancers (from diagnosis to death) given the full
benefits of modern therapy is certainly less than
five years. Yet the mean time of survival of what
must be considered as the most extensive group of
cancers which received no treatment at all was over
three years (from first symptom to death).
3. Great Variability of Growth Bate.
In Figure 1 is illustrated in graphical form,
the progress from onset of malignancy to death of
•the individuals in a series of cancers. The
abscissa measures time and the ordinate measures
the extent of spread. It will be seen that
although at the time of diagnosis differences in
the rate of spread between adjacent groups of
cancers may be so small that with our crude methods
of measurement we are unable to detect theia, never¬
theless a small difference in the rate of growth
(diminution in the slope of the line) will be
accompanied by a very appreciable increase in the
period of survival.
A group of patients with localised and slowly
growing cancers considered treatable at diagnosis,
would survive longer than the average and give a
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mean period of survival much greater than 5 years
even in the absence of treatment. If these
patients were in fact treated then this increase in
survival over the untreated would he attributed to
treatment, even although the treatment had no effect
whatever. By selection of patients with malignant
growths slightly less malignant than the average, or
by subdividing the total number of cancers iaio
groups by their degree of malignancy^and only
treating the less malignant cancers it is possible
to provide almost any cure rate that the therapist
desires in the particular group he chooses to treat.
4• Chronicity of Cancer.
Cancer is not only a very variable disease but
also a very chronic one. The effect of this is that
a therapeutic trial as conducted at present must
extend over a long period. Often the man who makes
the diagnosis or initiates the treatment is not him¬
self alive to analyse the end results if he has to
wait till the majority of the patients have died.
What he chose to call cancer at the end of his ex¬
periment is often somewhat different from what he
called cancer at the beginning. Since the number
of cancers seen annually at any one site by one man
is relatively small it takes many years, often a
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lifetime, to collect a series worth presenting.
Most large-scale investigations are derived from
collected hospital records extending over a period
of fifteen to twenty years. The accuracy and
assessment of the individual cases most vary
considerably depending on the particular clinician
who diagnosed them. The final figures therefore
reflect this variability which is not, and often
cannot be defined.
Five years is usually considered to be a
reasonable period of follow-up for all cancer deaths,
thile this may be true of cancers such as lung or
stomach it is certainly not true of cancers at such
sites as breast or rectum. Hence the criticism
voiced by some therapists that eight or ten years, or
even longer follow-up periods are essential. However,
the longer the follow-up period the greater the
proportion of patients who are lost sight of, the
larger the number who die of intercurrent disease.
However much mathematical ingenuity may be introduced
in allowing for these defects, there is little doubt
that if a treatment does not 3how better results at
any cancer site by the end of five years it is not
likely to show them at any time thereafter. If it
doesfthe most likely explanation does not lie in the
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efficiency of treatment but in a bias to including
■ ■
a number of cases which were not malignant at all.
5. The Failure to Employ Efficient Methods
of Analysis.
In cancer treatment the present day methods of
analysing the end results, the figures of which are
often biassed and inaccurate, are themselves open to
criticism on the grounds that these methods do not
take into account these variabilities and allow for
them. Mathematical analysis of the results of
cancer treatment is rarely performed by a professio
al mathematician and the results are rarely collect
in a way to be of value for adequate analysis.
The fallacies of Proportions. Nearly all the
present methods of presenting cancer statistics use
in some way a proportion as does the most commonly
used method - the five year cure or survival rate.
The difficulty in diagnosis means that the denomina¬
tor of the proportion is suspect and the difficulty
in assessing cure makes the numerator also a doubt¬
ful measure. Not only is such a proportion biassed
j
from the start but a proportion is not a very fine
statistic. Even if the proportion were derived
from unbiassed random sampling the variability in
'
the final figures merely as the result of such random
.
sampling is itself high. For example, the standard
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error of a proportion of 45$ patients claimed as
cured out of 200 cancers is 3.41$. That is, if a
further 200 similar cases were submitted to identi¬
cal treatment then there is one chance in three that
the proportion of cures would lie outside the limits
41.6$ to 48.8$ and one chance in twenty that it
would lie outside the limits 38.2$ to 51.8$. Using
this number of patients, in order to show that this
second treatment was significantly superior to the
first the five year survival rate in the second 200
cases would have to be at least 52$. 3y U3ing
proportions, if the improvement in treatment is only
of moderate degree, hundreds of cases must be used
to show this improvement.
The Fallacies of Staging. In cancer at certain
sites the curability rate after treatment differs
with the "stage" or extent of spread of the cancer at
diagnosis. Two series of cancer patients cannot be
compared as to curability if they contain different
proportions of patients at each stage. To attempt
to overcome this difficulty it has now become
customary to classify each series into groups by
extent of spread stage (or some other attribute
gauging malignancy).
However accurately the definition of each stage
is expressed in words, no two clinicians ever inter¬
pret the definition or assess the cancers in the
same fashion. This subjective error has important
consequences when the survival rates of the various
stages are compared in the two series.
If the first observer of the same series has
a lower threshold for diagnosing and assessing
malignancy than the second, then at each stage he
will include a number of patients whose cancers were
of a lower degree of malignancy than those of the
corresponding stage group in the other series. The
curability in each stage will be found to be higher
in the first assessment because the constituent
cancers at each stage are on the average less
malignant than in the second. Since the assessment
of malignancy at diagnosis is so crude then compari¬
son of stage cure rates in two independently assessed
series is not of much value. Staging, unless the
assessment is made by the same man in the two series
merely perpetuates in as great a degree the error
which it was designed to avoid.
As long as present methods of assessing malig¬
nancy are so unreliable the only good way of compar¬
ing the results from two centres of treatment is to
compare the behaviour after diagnosis, whether the
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individuals are treated or untreated,killed or cured,
of every individual coming for diagnosis to one
.
centre,with every individual coming for diagnosis to
the other centre. Preferably the two centres should
each drain a fixed geographical area. The random
variability of occurrence of different types of
cancers in contiguous geographical areas is likely
to be much less than the biassed variability that
occurs in selection of patients for treatment and
inclusion in the five year survival rate.
Summary. 'The diagnosis of cancer is vague
and uncertain. The variability of behaviour of
individual cancers at any one site is great even in
the absence of any treatment. The methods of
counting the cures are crude. We are never sure of
what we are claiming to cure and we do not know how
much the treatment modifies the behaviour of what we
think will prove to be a malignant tumour.
,
/hen two series of cases are presented with
different cure rates, this difference in the rates
is the sum of the differences of at least these
1
factors;
1. The difference actually due to the treatment
itself.
2. The differences that might occur merely by
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chance In any proportional index particularly if
the sample is small.
3. Biassed selection of the cases so that the
two series do not contain the same proportion of
cancers in each grade of malignancy.
4. Differences in the standard of diagnosis.
There is little doubt the last two factors
account for the major part of any differences
observed.
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II. THE PROOF OP THE CURABILITY OP CANCER.
Some modern cancer therapists have ceased to
talk of cure as their objective and are satisfied
with a prolongation of life, presumably because
cure is difficult to achieve or difficult to
measure. If cancer is as curable as is claimed
and our current ideas of cancer behaviour are
correct then the effects of treatment should be made
obvious
1. In a fall in the death rate.
2. In the fact that the earlier the diagnosis
the higher the cure rate.
1. That the expected fall in the death rate has
not occurred is obvious from examination of Tables
I & II. If the death rate from cancer had fallen
it would have been claimed as proof of the efficiency
of treatment. Since it has not, then its absence
is most likely due to the ineffectiveness of treat¬
ment. Ho valid argument has been brought forward
to suggest any other conclusion.
2. Since the object of treatment, certainly
surgical treatment, is to eradicate the primary site
of grorch before it has spread beyond the limits of
surgery, then the earlier the treatment is under¬
taken the less extensive the cancer and the higher
- 27 -
the hope of cure.
Yet when the figures correlating cure rate and
the duration of symptoms are examined the expected
correlation is not found. falters Gray & Priestley
(1941) found on examination of the records of 11,000
cases of cancer of the stomach that 2,840 were
considered suitable for resection of at least part
of the stomach. Of the patients with resectable
cancer; 45$ had a duration of symptoms of less than
one year before treatment,while in the others not
suitable for resection 54$ reported a duration of
less than one year. ihen the relationship between
survival and duration of symptoms was examined it
was found that those patients whose symptoms were
present for less than one year the five year survival
was only 25$ whereas for patients whose symptoms had
lasted more than one year the five year survival rate
was 32$.
Similarly Lane-Claypon (1926) found that 58$
of breast cancers of stage II with a five year
survival rate of 25$ had symptoms of less than 6
months,while the proportion of cancers in stage I
with a survival rate of 75$ who had symptoms of less
than 6 months was 63$ - a proportion not signifi¬
cantly different from the stage I cancers.
Park and Lees (1951) investigated this problem
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in more detail with respect to cancer of the breast
and came to the conclusion that published figures
failed to confirm the assumption that earliness of
diagnosis was correlated with curability.
The usual and probably correct explanation for
this"paradox"is that the more rapidly growing
cancers have a shorter duration of symptoms before
treatment and a shorter period of survival after it.
But this does not explain the absence of the
supposed relationship between duration of symptoms
and curability. With the large series of cases
which have been examined such a relationship ought
to be detectable if it exists. Although the
variability in malignancy of cancers which have shown
symptoms for 6 months may be very wide, according to
theory the overall cure rate (or average survival
time) for an identical group of cancers treated at
4 months ought to be much greater. The difference
should represent that proportion of the group which
spread from the ciirable into the incurable zone in
the two months.
Again, according to Dukes (1940) the surface
area of a primary cancer of the rectum at the time
of treatment is roughly constant. (The size of the
primary cancer in any particular part of the rectum
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required to produce equally intense symptoms would
not "be expected to vary by very muesli.) But Bukas
also states tiiat there is no relationship between
the size of the primary and the extension of the
secondary deposits at diagnosis. From this one
might make the inference that the occurrence of
metastasis bears no relationship to the duration of
the symptoms. Since curability is proportional to
extent of spread one can reasonably argue that
duration of symptoms before treatment bears no
correlation with curability.
Extent of spread at diagnosis at any site is
not an indication of the time for which the cancer
has been growing but rather an indication of its
inherent malignancy or rate of spread. The
principal correlation with long survival after
diagnosis is not the earliness in diagnosis but the
inherent low malignancy of the cancer.
Conclusion. From this we conclude that
treatment of cancer does not prevent metastases if
these are going to occur and in those cases which it
is effective at all it merely prolongs life. How
effective it is, is difficult to determine from the
data usually presented in cancer statistics.
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III. THE THEORIES OF CANCER BEHAVIOUR
AITS THEIR ITOPEffCE OH TREATMENT.
The Present Concept of Cancer and Its Influence on
Treatment.
The dissemination of a cancer has "been
considered to occur an appreciable time after the
appearance of the primary, leaving an interval
sufficiently long to permit diagnosis and successful
eradication of the primary in many cases.
The opinion has been expressed in the last
paragraph that treatment based on this hypothesis
has not proved very effective. This does not of
course prove the theory wrong since obviously cancer
does start locally, but it does suggest that in many,
if not the majority of cancers dissemination occurs
before the diagnosis of the primary cancer is
possible.
Treatment directed to complete eradication of
the primary cancer often, perhaps always, fails to
prevent metastases if these are going to occur,
while treatment of the accessible tumours often has
surprisingly beneficial results, even when it is
known that all involved tissue has not been removed.
Removal of a tuberculous kidney or lobe of a lung
often does restore a patient to relative good health
although no surgeon would claim he had excised all
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the tubercle bacilli in the body. Whether the
patient recovers or not depends largely on restora¬
tion of his immunity by the removal of an infective
mass and diminishing for a time the virulence of the
infection. It is possible, that in a patient
suffering from cancer, removal of a malignant mass
may restore the "immunity" or growth control
equilibrium to the body so that metastatic deposits
are temporarily suppressed. Such a theory would
explain the occurrence of secondaries twenty five
years after removal of a primary cancer or the
regression, admittedly usually temporary, of the
secondary deposits after the primary is removed.
Surgery. Since cancer has been assumed to be
a local disease its treatment could be claimed to
lie in the province of the surgeon. In spite of
great advances in surgical and anaesthetic technique
permitting longer operations and wider fields of
excision,the results of surgery are not impressive
in the treatment of the great killing cancers such
as lung, stomach, breast and colon. Yet surgery,
if the cancer is accessible, is the most logical and
probably the most efficient form of treatment since
it does at least remove the malignant cells in the
field of operation.
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Radiotherapy. The object of radiotherapy is
to kill all the malignant cells by subjecting the
area of infiltration to a penetrating beam of X-Raya.
Unfortunately, the lethal effect of irradiation on
the cancer cell is not specific and the cancer cell
is more susceptible than the normal cell only in so
far as it is more rapidly dividing and metabolising.
The limiting dose in the use of radiotherapy is
therefore the lethal dose for normal tissue, .Vhile
it is possible that radiotherapy might sterilise, a
superficial area from malignant cells, at deeper
levels it is almost certainly inferior to surgical
excision of the affected area if this is localised.
It has the advantage over surgery, however, that it
can reach areas inaccessible to surgery. However
the "magna therapia sterilans" which the radio¬
therapists claim must be rarely, if ever achieved.
The full usefulness of surgery and radiotherapy
have been already exploited to the full and little
more can be expected from those techniques.
Chemotherapy. So far no drug has been
introduced which will cure cancer, nor in fact any
drug with the possible exception of stilboestrol,
which will appreciably slow the growth rate of a
malignant tumour. Hundreds of drugs have been
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tested which will Inhibit temporarily the growth of
cancers in mice and some of them have "been tried in
the human, but without success. Any injurious
procedure applied to a mammalian body, including the
human, which bears a cancer will temporarily reduce
the growth rate of the cancer. This is again
■f-
merely the result of the increased susceptibility
of rapidly proliferating tissue to injury by non¬
specific toxic or traumatic procedures. These
chemotherapeutic agents are effective (temporarily)
in direct proportion to their toxicity - that is
they have a low therapeutic ratio (Lees & Lees 1951).
It is doubtful if any chemotherapeutic agent known
at present equals radiotherapy in efficiency.
A Concent of Oancer.
Since the current concept of eancer behaviour
is unacceptable because it fails to explain the
observed facts, it is necessary to attempt to evolve
a theory which will be compatible with the facts.
If possible an attempt should be made to
reconcile the vast amount of information collected
in the last 20 years about induced animal cancer
with what is known about human cancer. (As far as
the radiotherapist and surgeon are concerned they
would carry out exactly the same techniques as they
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use at present if no experimental research had been
done at all.)
In most definitions of cancer by pathologists
the adjective "uncontrolled" or "uncoordinated" is
usually applied to the growth of the tumours
conveying the impression that some higher mechanism
does, in fact, exert a controlling influence on the
organisation and function of each normal tissue.
That any tissue is under the influence if not the
control of numerous other tissues is self-evident.
But it is only recently that attempts have "been made
to investigate experimentally the influence of
general natural "controlling" factors in the host on
the growth rate of induced tumours,and little
investigation in the human has been made so far.
Most pathological writers although they may have
defined cancer in some way as an "uncontrollable'
growth nevertheless systematically classify cancers
according to common sites. An investigation and
subdivision of cancers by their mode of behaviour
has therefore been rarely attempted and modern
pathologists e.g. Willis (1948), still cling to a
"local" classification as opposed to a "general" or
"behaviourist" classification of cancer.
Much difficulty could be avoided if cancer were
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considered to be a local manifestation of a systemic
disease. Cancers arise through a failure to con¬
trol growth on the part of the body as a whole, -
cancer is a degenerative systemic disease which
frequently results in death. More attention might
be paid to the factors which result in the failure
of control rather than the results of the failure,
i.e. the discernible tumours themselves. It has a
resemblance to hypertensive arteriolar disease in
which one tissue may fail to function adequately and
lead to death of the whole. But just as in cancer,
the tissue which ultimately fail3 may be any one of
many.
At birth each tissue can be postulated to be
endowed with a functional life span. During the
life span of the tissue the intensity and amount of
activity which it undergoes is dependent partly on
internal metabolic factors brought to bear on it by
other tissues, and partly by external factors
present in the environment in which the body moves.
The external factors may influence the specific
tissue directly, or indirectly.
A tissue can then be assumed to be hereditarily
endowed with a certain number of metabolic cycles.
;hen these are expended death will occur and the
TABLE IV.
AGE INCIDENCE OF CANCER.
FEMALES.

















Haerao- poietic Systera Buccal CavitySt Pharynx Total
30 - 27 48 17 16 16 46 4 255
35 - 52 155 37 44 37 47 6 525
40 - 93 288 54 64 65 59 12 889
45 - 139 448 96 123 114 63 26 1454
50 - 220 564 141 201 189 93 30 2219
55 - 282 732 213 304 294 127 48 3114
60 - 313 831 293 607 455 163 58 4174
65 - 322
, 994 396 994 714 189 83 5699
70 - 303 1145 424 1499 1150 209 115 7489
75 - 430 1448 469 2193 1812 234 150 9637
80 - 316 1735 487 2793 2524 178 185 12400
85 + 394 2402 409 2667 3091 136 318 14203
Table IV. Mortality Rates per Million Living by
Age and Sex for Some Common Cancer Sites.
Derived from Tables 1 and 17 of the Registrar
General's Statistical Review of England and
/ales for 1951.
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tissue will cease to integrate with, the other
tissues. This tissue death may take the form of
atrophy and fibrous replacement or it may take the
form of independent proliferation, i.e. neoplasia.
By this hypothesis, as far as the human is
concerned, the most important cause of neoplastic
development is merely tissue exhaustion from the
normal wear and tear of survival. In only a few
cases e.g. tar cancer, osteomyelitis sinus cancer,
some bladder cancers, is a tissue subjected to a
known abnormal external stimulus which will precipi¬
tate exhaustion to the onset of malignancy. The
mammalian body starts to die of cancer from the
moment of conception. The principal "cause" of
human cancer is ageing. This is very clearly
brought out in Table IV culled from the Registrar
General's figures for 1951. From this it will be
seen that at the common cancer sites the incidence
increases steadily with advancing age.
Chemical carcinogenesis in the experimental
animal or the human can be considered to arise
because the tissue is subjected to an abnormal
stimulus as the result of the presence of the car¬
cinogen. The allotted span of metabolic cycles
would then be used up more rapidly. The action of
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these compounds in the causation of cancer can he
compared to the action of the sulphonamide drugs in
inhibiting the growth of bacteria.
hen a carcinogenic hydrocarbon is applied to
a tissue, then some of it is absorbed within the cell
and because of its resemblance to a natural steroid
is taken into the metabolic cycle. Since it is not
identical with the normal steroid the particular
enzyme system into which it has been incorporated
fails to complete its chain-reaction cycle and either
stops short or continues in an abnormal fashion.
If the amount of the carcinogen within the cell is
high then death of the cell results. If it is low,
because of its insolubility and because it is firmly
fixed chemically tq some cell constituent, then the
cell will survive with an impaired enzyme system.
To compensate for the failure of part of the enzyme
system the remaining enzyme systems must work over¬
time or, possibly the disorganised enzyme system is
subjected to further strain. If the cell is sub¬
jected long enough to these abnormal conditions then
a "mutation" will occur. By successive cell
division a race of cells will develop which will be
capable of survival without the use of a particular
group of enzymes which are essential for survival of
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the normal cell. Function of these new enzymes
is no longer dependent on integrated control and a
race of malignant cells arises which are capable of
a semi-independent existence.
Such an hypothesis will explain the continuous
graduation of malignancy,i.e. degree of infiltrative
and metastasising capacity which is found in human
cancer. Degree of malignancy will roughly parallel
the number and the importance of the enzyme systems
which the malignant cell has developed independent
of the control of the host. There is no necessity
to postulate a sudden irreversible change in the call
before which it is normal or benign in character and
after the change it is irretrievably malignant.
Although a sudden irreversible alteration in one
enzyme system may occur, before the onset of frank
clinical malignancy such alteration may have to
occur in a succession of enzymes. The number and
type of abnormal independent enzyme system^' required
to induce this state will vary from tissue to tissue
and from individual to individual and from time to
time. The steps on the road to malignancy are made
of enzyme systems or potentials for differentiation
and not of cells. Minor degrees of abnormality will
not necessarily lead to malignant neoplasia, either
- 39 -
because the host regains control over the prolifera
tive activity of the group of abnormal cells or
because of failure of the new abnormal enzyme systems
to survive.
Influence of the Concept on Choice of Method of
Analysis.
By this conception cancer can be considered as
the resultant between the attempt at autonomous
growth on the part of the tissue and the attempt of
the body to re-exert its ordered control over that
growth. If the local growth asserts its autonomy
then it need not necessarily grow and spread at a
constant rate.
Once however the cancer starts to infiltrate,
even although its apparent rate of spread is slow,
emboli are being thrown off. If the host still has
an high degree of control none of these emboli will
tahe. When however the primary cancer achieves a
certain volume, the partial control of the malignant
cell diminishes even further and a metastasis may
tahe. There is not only to be considered the
growth rate of the primary mass of cancer cells
which is probably logarithmic, but also the metas-
tasising potential which will depend partly on the
size of the primary mass itself. The reaction
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"between the host and the cancer can be compared to
the law of mass action in chemistry. The rate of
spread will depend on the "concentration" of
malignant potential in the cancer cells and the
"concentration" of anti-cancer factors in the host.
By removing a large mass of primary growth the rate
of the reaction might be slowed or even halted and
the equilibrium restored. Ihen more is known of
the science of cancer and we are able to measure
more accurately the factors involved it might be
possible to devise some formula to predict rate of
spread similar to that which the chemist uses to
predict the rate and direction of a chemical
reaction.
At present however all we can do is to measure
what factors we can and find out how long it takes
the patient to die. By examining the behaviour of
a series of cancers we might by working backwards be
able to derive some general law.
This contention that for practical purposes
cancer should be considered as incurable has been
misunderstood,(that is cancer which it is believed
possesses metastasising power). Firstly, it has
i
been interpreted to mean that all present treatment
is useless. This is not so. No such assertion
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was made. What is meant is that, although treat¬
ment may be of little avail on the average, the odd
ease occurs in which it is highly effective. But
nobody so far has investigated why it was effective
in the odd case.
Secondly, it is held that when the surgeon
excised an "intra-epldermal" carcinoma of the cervix
he can legitimately claim to have cured a cancer if
the patient lives to the natural period and does not
die of cancer of the cervix. It is impossible to
deny that these cases have been prevented from the
possibility of dying of cancer of the cervix but it
is equally impossible to deny that many of the
"premalignantM lesions would never have become
infiltrating cancers. It is necessary to deal in
terms of the average survival of a group of patients
with similar "premalignant" lesions. Assume there
is a one in five chance that a premalignant lesion
of the cervix will become malignant five years later
and will kill the patient three years after that.
The survival period of this patient is eight years
compared with the twenty five years of the other four.
This gives the survival of untreated premalignant
lesions of the cervix as just over 23 years. By
amputating the cervix in all five women the surgeon
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can claim to have increased the survival of patients
with such lesions from 23 to 25 years.
To refuse to call these successful treatments
"cures" may he quibbling. But every normal tissue
is potentially malignant and if it is argued that
after removal of premalignant tissue it is justifi¬
able to claim a cancer cure then the extreme form of
this argument is that every woman should have the
breasts and uterus excised at the age of 35 since
these are two sites at which the probability of
malignant change is high. The surgeon would cure
the great majority of cancers of the breast and
cancers of the uterus but might find these patients
still developed cancer at some other site later.
Even if the claim that excision of a pre¬
malignant lesion prevents a cancer death is accepted
such treatment will have a negligible effect on the
overall cancer death rate. There is no harm in
regarding the object of treatment as the diminution
in the number of cancer deaths and not as the in¬
crease in the number of cures. This objective is




1. The principal "cause" of cancer in the human
is ageing. With our present knowledge a search for
specific "causes" is likely to prove barren in the
foreseeable future and hence the chance of
"preventing" cancer is not very great.
2. The behaviour of the host, i.e. the behaviour
of all tissues other than the malignant tissues, is
of equal importance to that of the cancer in deter¬
mining the period of survival after overt tumour or
tumours have appeared.
Any method of assessing curability of cancer
should, if possible, indicate the relative importance
of any factor in the host, the cancer or the treat¬
ment which has played a part in causing or preventing
the patients* death. Cancer research in the human
has been dominated by the cellular morphology of the
tumours. Other and possibly more important factors
in the cancer and the host have been largely ignored,
3. The adoption of this attitude to the cancer
patient would not alter present methods of treatment
by very much but by considering the patient as well
as the cancer facts might come to light which would
give us understanding of the cancer process and
prove of value in treatment and prognosis.
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4. In view of the multiplicity of possible
"causes" most of them unknown, treatment at present
can only he and is, of a non-specific type. A
single ehemotherapeutic substance which will
specifically inhibit the growth of most or all
cancers (and have little or no effect on non¬
neoplastic tissue) is unlikely to be found. Anti¬
biotics are effective against a wide variety of
organisms which possess a common (normal) ensyiae
system which can be inhibited. But the same
abnormal "malignant" enzyme system may never occur
in two cancers since no two cancers are ever identi¬
cal in behaviour.
5. Since Radiotherapy and Surgery in cancer
treatment are unlikely to advance further and since
the science of the chemotherapy of cancer is in its
infancy, the prospects of rapid advances in cancer
therapy in the foreseeable future are small. The
drug that sets us on the road to success will be one
which merely prolongs life. Our methods of analysis
must be sensitive enough to appreciate even a 3mall
average prolongation of life. The benefits of
treatment show a continuous gradation and cannot be
assessed in all o.r none terms.
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IV. AH INDEX OF GANGER BEHAVIOUR.
The Best Index of the Effects of Treatment.
It is required to obtain a numerical index
which will summarise cancer behaviour with or without v
treatment. The index should fulfil these criteria
1. It should be simple.
2. It should be applicable to and suitable for
all cancer types whether treated or untreated.
3. It should be applicable to present and future
forms of treatment.
4. It should indicate, if any, the beneficial
effects of treatment. These should be shown as
early as possible after the start of the experiment.
5. The accuracy of the index of the behaviour
of the group of cancers under discussion should be
so defined that the significance of any difference
from that of another group can be estimated by
methods which will satisfy the statistician.
6. The data from which the index is derived
must show the relative importance of any factor in
the cancer itself or in the host or in the treatment,
which might have played a part in the final outcome.
Only thus can advances be made.
7. The index and data should be presentable in
such a way that their validity is unquestioned. If
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%
possible, the examination of the figures themselves
should give an indication of the accuracy of the
clinical assessment on which the claim for the
treatment is based.
'
fhe Benefits of Treatment. fe wish then to
estimate the benefits to be derived from cancer
treatment insofar as these can be given a numerical
value.
'
fhe ideal benefit is complete cure. At many
I
cancer sites complete cure cannot be assumed even if
the patient survives for twenty or more years.
Conversely treatment might alleviate pain and misery
and not necessarily increase the number of cures
although it might be still highly beneficial.
But it is unlikely that any treatment which
"cured" some cases of cancer, assuming that such a
form of treatment exists, would not also prolong the
f
life of those who were uncured. Although it might
have little influence on the misery of the terminal
stages it would prolong the period of relative well
being preceding them. fhe object of treatment then,
is to prolong life.
In assessing the benefits of cancer treatment,
although there are other factors which are immeasur¬
able and yet important, the easiest factors to




Figure 2. The Life History of an Untreated
Cancer and the Possible Effects of Treatment.
T = Point at which treatment given.
D « Point of death,
a = Immediate cure.
b = Regression to disappearance,
c = Arrest of growth,
d « Progression at a slower rate,
e = Treatment ineffective.
o,s,r,g,l, as in Figure 1.
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these the time from diagnosis to death is the
simplest and the most reliable.
The best treatment will be that which prolongs
the life of the greatest proportion of patients.
The bast index will be that which summarises simply
and accurately a formula applied to estimate this
prolongation of life.
.'/hat Do We l?ish to Meg jure? Basically we wish
to evolve an index or formula which will measure the
growth rate of a cancer with or without treatment.
The problem can be put graphically. In
Figure 2 the ordinate measures the proliferativeneas
of the cancer, that is the extent of spread at any
point in the life of the cancer. The abscissa
measures the resistance of the host, that is the time
the cancer takes to achieve a certain degree of
extension or to cause death. The life and rate of
spread of an untreated cancer are represented by the
line OD, 0 being the point of origin of the cancer
when irreversible malignancy set in, and D the point
of death. The ordinate can be measured in stages
of the life of the cancer 3ueh as clinical appearance
of-the primary tumour, occurrence of local metastases,
generalised dissemination.
If we could fix two points on this line before
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treatment we could calculate its slope (i.e. the
growth rate of the cancer), and by producing the
-
line from the point of diagnosis and treatment (T)
find the point at which the cancer tissue would be
of sufficient bulk to cause death. (The assumption
is made that the growth rate is constant during the
life of the cancer. This may not always be
correct.) If the patient were treated and the
growth rate thereafter observed, having fixed the
point T we could plot the subsequent course of the
cancer after treatment. ;
The possible courses of the cancer are shown
by the dotted lines in Figure 2 namely (a) immediate
cure, (b) regression to disappearance, (c) arrest,
(d) progression at a slower rate, or (e) progression
at the same rate. The change in the slope of the
line after treatment or the difference between the
time of death after treatment and the expected time
of death without treatment will be the measure of the
value of treatment.
Unfortunately -
1. We have no accurate method of assessing
the rate of growth after treatment and still less
before it*
2. The point T on the line cannot be fixed
FTSUBE 3A
~i i i r
0 I 2 3
TIME AFTER DIAGNOSIS
Figure 3A. The Behaviour after Treatment of the
Individuals of a Series of Cancers thought to he
of the Same Degree of Malignancy at the Time of
Diagnosis.
T. = Average of extent of spread in the
individuals at the time of diagnosis.
,,©2*" ~ = Times survival of individual
patients after diagnosis.
Ba * Average time of survival -after diagnosis.
o»s,r,g,l, as in Figure 1.
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with any certainty since we do not know accurately
the extent of spread or the point in its life his¬
tory which the cancer has reached at the time of
diagnosis.
3. We accordingly do not know exactly how
the cancer would have behaved in the absence of
treatment.
The only coordinates we know with certainty
are those for death and the point of time at diag¬
nosis (as measured backward from the death point).
The coordinate for extent of spread at diagnosis is
ill-defined.
The behaviour after treatment of a group of
cancers all of which as far as could be Judged
*■.
clinically were of the same degree of malignancy and
all of which had passed through the same fraction of
their life history at the time of treatment is
illustrated in Figure 3A. sVe can only assume that
the average figure for the group for the extent of
spread coordinate of T lies somewhere near the centre
of the zone within which the coordinates of extent of
spread at diagnosis of all the caneers are presumed
to lie. By measuring the time interval from T^to D
in every member of the group we get the average time
of survival after treatment and can calculate the
FIGURE 3B
Figure 3B. The Subdivision of the Series of
Cancers shown in Figure 3A into Three Groups
by Means of a Factor Known to Influence
Malignancy and possessing Three Degrees of
Intensity.
Da,,D.9,D., = Average time of survival ofax At A3 the individuals in each
of the three groups.
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variability round this average. fe thus measure
crudely the average rate of growth after treatment.
By the measurement of factors which we believe
•
would influence or be associated with the growth, we
might be able to more accurately define the rate of
growth and so diminish the variability of behaviour
.
as measured round the point D^. Our group of
cancers might be subdivided by classification by a
further factor of which three degrees of intensity
can be recognised. Provided the intensity of this
factor is related to the rate of growth the main
group could be subdivided into three subgroups whose
behaviour could be diagrammatically shown in Figure
3B. The variability of behaviour is thus seen to
diminish within each subgroup and we are able t
slopes of the lines after treatment. For the
tanglement of the relationship of each factor to one
another and the influence of each factor on the
growth rate it will be necessary to resort to
mathematical analysis of the data by "analysis of the
variance" or by "analysis of multiple regression
I
lines". Graphical representation has however much
value in showing possible trends and relationships
and does not demand an high degree of mathematical
accurately define the points DA1' 3)A2, etc., an
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skill as these procedures do.
Ideally these measures of the average rate of
growth after treatment 3hould he contrasted with what
would have heen the average behaviour without treati
ment of the same group of cancers. Possibly by
examination in retrospect of the data of the results
of treatment we might get some idea of the behaviour
without treatment. Since at present we cannot even
compare the treated cancers with another exactly
similar group of untreated cancers then it is only
possible to use some indirect standard for compari¬
son. This in effect means comparison with the
behaviour of control patients who did not have
cancer, or preferably with that of an exactly similar
group of cancer patients treated by another method.
Comparing the Efficiency of Established or Sew
Treatments.
It is frequently argued that it is unjustifiable
to carry out trials of new methods of treatment on
patients because we might deprive the patient of
established and reasonably good treatment for the
doubtful benefits of a new treatment. There is
however no other way of assessing the value of a new
treatment. If common sense and medical judgment
consider it hopeful, then it is justifiable to carry
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out a trial provided it is carried out in a fashion
.vhich will give a definite result - "better, worse or
equally good. To obtain this result the best
planned experiment will be that which uses the
minimum number of patients and the minimum time.
The following points are of importance in
planning such an experiment.
1. If the new treatment is a drug then its
possible mode of action and its dosage should be
investigated in the laboratory before it is tried
in the human. Some attempt should be made to pre¬
dict its toxicity and therapeutic ratio - how
specifically is the drug antagonistic to cancer cells
and not just to cells in general?
Merely because a drug, chosen for no particular
reason, has been shown to inhibit transplanted
tumours in mice is no justification for therapeutic
trial.
2. The type of cancer first chosen for test
should be one with a narrow range of behaviour or
one in which the cancers can be divided into groups
of uniform malignancy. Although any general chemo-
therapeutic agent which was effective against one
type of cancer would be unlikely to have no effect
on another, the choice of say bronchogenic carcinoma
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which is almost invariably and rapidly fatal means
that if the drug had any inhibitory effect at all
it would be quickly obvious with even a few cases.
'The Leukaemia-Lymphosareoma-Hodgkin group of
cancers are most frequently used for drug trials but
they are not satisfactory. The range of behaviour
in the group is very wide and more important, it is
very difficult to forecast the subsequent behaviour
of any member of this group of cancers with our
present methods of diagnosis. To show a significant
effect therefore there would be required a very lsr
number of patients unless the effect was very strik
Since the cells of this group like their normal
counterparts are highly susceptible to non-specific
toxins,there is a tendency to claim "encouraging
results" after treatment by what was merely non-
• 1
specific toxaemia.
3. The treatment should theoretically be
given as early as possible in the course of the
disease since it is probable that in this way it
will be most effective in prolonging life. The
immediate beneficial effect might be most obviously
found in a moderately advanced cancer of moderate
malignancy where the change in growth rate would be
more easily observed.
Usually however untested treatment Is likely
to he first tried out on patients with cancers in
which other treatment has failed or which are un-
treatable by other means. It is mainly for this
reason that the unsatisfactory haemopoietie group
of cancers are commonly used for trial of a new drug.
4. Apart from those involving time the choice
of the factors by which we can measure the value of
treatment is difficult. The advance of the tumour
as indicated by the number, extent, and site of the
metastases would be the best guide since cancer by
and large kills by its mechanical bulk. Unfortun¬
ately this is difficult to assess clinically and in
some cancer types like leukaemia, chemotherapy may
produce massive necrosis of malignant cells without
necessarily prolonging life;(such treatment may even
shorten it).
Similarly, in assessment of the patient's
health, the change in body weight or other general
measure often fails to show correlation with the
progress or regression of the cancer.
5. The results must be Interpreted with
common sense. The validity of the conclusions
drawn from the results will depend largely on the
accuracy of the assumptions which were put forward
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at the start of the experiment. 3y altering the
assumption it is possible to draw two entirely
different and sometimes diametrically opposite
conclusions from the same results.
Jor example, Stocks (1952) found that the
incidence of cancer of the lung in urban districts
in England & Vales is roughly proportional to the
density of the population. One cannot quarrel with
this mathematical correlation.
How Stocks started with the assumption that an
important factor in the causation of lung cancer .vas
the inhalation of carcinogenic substances present in
the atmosphere as the result of industrial pollution
Since atmospheric pollution increases with
industrialisation and concentration of population,
his findings led him to assert that his assumption
was correct and that industrial 3moke was an
etiological factor.
But an entirely different assumption could be
i'
made, (which is the more probable one in the writer*
opinion). The facilities for the diagnosis and
treatment of surgical che3t conditions are concen¬
trated in specialised units. These units tend to be
located in densely populated areas although the
patients sent for treatment might come from suburban
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or rural areas. Deaths are registered in the
district in which the patient died and not in the
district of domicile. The assumption is made that
the incidence of lung cancer deaths in any town is
proportional to the number of beds available for
diagnosis and treatment of that disease in the town.
The findings confirm this assumption and imply-
that industrial smoke is not an etiological factor
in cancer of the lung.
6. The principal source of error and confusion
in cancer statistics lies not in the mathematical
analysis of the figures themselves. It is the
method of collection of the data which is suspect.
However elaborate the subsequent analysis, this will
never compensate for biassed judgment by the thera¬
pist at the time of diagnosis and treatment.
7. If possible, the results should be
presented in such a fashion as to permit them to be
contrasted with the behaviour of untreated cancer.
The Conduct of the Therapeutic Trial. Briefly
the experiment will be carried out in this fashion.
1. The type of case to be used for trial
should be defined.
Every case of this type coming to the
clinic must be included in the experiment.
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3. Any factor in the host or the cancer which
might influence the effect of treatment or a change
in which might indicate the efficiency of treatment
should he measured. This measurement should if
possible he made "by someone who will not carry out
either the control or the test treatment.
Some variable factors such as duration of
symptoms can. be given numerical estimation, others
might be only recordable as being present or not
present, while others can only be roughly divided
into three or four degrees, S3 in recording state of
health. These measures however crude v/ill have
statistical validity provided they are made by an
unbiassed judge.
4. The patient is then allocated purely by
chance to. one or other treatment, e.g. by the toss
of a coin, or by allocating alternatively to each
treatment.
5. The patient i3 then treated.
6. After an appropriate interval the patient
is again reviewed preferably by the original assessor
and preferably by one who does not know which treat¬
ment each patient has had. . The factors previously
assessed but which might have altered as the result
of the advance of the disease or of the effect of
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treatment are again measured. Those patients who
die under treatment should if possible be similarly
assessed at the time of death and certainly the time
of death recorded.
7. The figures are analysed by a professional
statistician who will assess with stated degree of
accuracy the probability that any differences in
behaviour between the two groups was due to treat¬
ment. He will also assess the importance of any
other factor which might have influenced the end
result.
It is customary at this point to add that, of
course the statistician should have been called in
in the first place before the experiment began.
This cannot be denied. Unfortunately the mathemati¬
cian cannot make the clinical measurements to ensure
these are unbiassed. lor can he usually suggest
which factors are likely to be important in the out¬
come. These can only be determined by the clinician
whose clinical skill and judgment of cancer will be
decisive in the choice of factors which he considers
important.
dalle accuracy in assessment is important since
it will diminish the variability in the individual
survival times in each class, what is much more
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important is that the standards of diagnosis should
he the same in the two series being compared.
Overdiagnosis of cancer by 5$ is relatively un¬
important provided that the non-cancer patients are
as likely to he subjected to one form of treatment
as the other. If the radiotherapist insists on
himself making the selection and stratification of
patients which he considers suitable for radiotherapy
and the surgeon permits the surgical pathologist to
do the stratification for him, then the two series
are not comparable since the standards of assessment
are not the same. Unless like is being compared
with like, t@3ts of significance are misleading.
It is also necessary to emphasise that the
initial assessment (however crude) of the characters
of the tumour must be made at the time of diagnosis.
Assessment in retrospect with knowledge of the out¬
come, will be subject to so much self deception, that
the figures will be worthless.
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V. CRITICISM Off PRESENT METHODS 0? AKALYSI3.
Before an attempt is made to evolve a method
of analysis which will permit the measurement of the
Benefits of treatment in the fashion suggested the
two common methods of recording cancer results will
he discussed.
The give Tear Survival Rate.
The five year survival rate fulfils only one
of the criteria of a good index,namely simplicity.
Apart from this it has many disadvantages. These
spring mainly from the fallacies - that cancer
diagnosis is certain and is either positive or
negative, that treatment is entirely curative or
completely ineffective, and that cancer at any site
behaves in an uniform manner. The principal
disadvantages can he listed.
1. The five year survival rate is not a 5rue
index of the value of treatment. It implies that
in the absence of treatment the survival rate at
five years would have been nil. At some cancer
sites the survival rate at five years for untreated
or even untreatable cancer is appreciable. A five
year survival rate after treatment should be con¬
trasted with the survival of similar cancers without
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treatment. He axe interested in the increase of
survival time due to treatment and at present our
idea of the survival of treatable but untreated
cancer is very vague.
2. By only recording the number alive at
five years it fails to indicate the benefits to
those who died within five years,but whose life was
prolonged appreciably but not quite for five years,
lor does it indicate the benefit to those who would
have lived for five years without treatment.
3. It assumes that death from cancer if it
is going to occur occurs within five years. Since
even at those sites which are claimed to be partially
curable,the rate of dying after the fifth year of
cancer patients is still greater than the rest of
the population,this assumption is clearly false.
4. Although 5 years is the longest period
for which patients can be followed with any degree
of accuracy or convenience there is no reason why
five years should have been chosen as the ideal time
at which to show the maximum value of treatment at
all cancer sites. Treatment might increase the
survival time of all bronchogenic carcinomas by 100$
yet the five year survival might still be less than
one per cent. Assuming that some cases of
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bronchogenic cancer can be cured by treatment then
this would be obvious by three years, when about
98^ of treated and untreated cancers at this site
would have been dead.
5. The survival rate is a proportion and cannot
be any more accurate than the numerator or denomina-i
tor of that proportion. The principal error is
likely to lie in the denominator due to selective
overdiagnosis of cancer and the survival rate ignores
or exaggerates this error.
The numerator is less open to criticism since
the number of survivors at five years can be counted
although they may not be "cured".
6. As the result of failing to measure other
possible benefits of treatment at other times the
data can only be divided by one attribute - survival
for five years. Such a proportion is subject to
great random variability between sample and sample
dravan from the same ma3s of cancer patients at any
site.
7. It is difficult to assess the effect of
treatment on those patients who die from other causes
or who are lost sight of before five years. If
patients who die of intercurrent disease are excluded
no account is taken of the influence of the cancer in
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precipitating death, or of treatment in delaying
death. The failure to attend may be due to death
from cancer.
This source of inaccuracy can be partly
corrected by the construction of a Life Table and so
obtaining the mortality rates for each year based on
the number known to be alive at the beginning of the
year. From this the probability of survival to the
end of each year up to the fifth can be calculated.
This procedure of course only minimises one of the
fallacies in the collection of the data themselves
and does not correct the errors of the five year
survival rate as such.
The Survivor Table and Curve.
The survivor table is a useful method of
presenting the results of cancer treatment and it
has many advantages over the five year survival rate
whieh only uses the figures for the end of the fifth
year. The data can be presented graphically by
plotting the number of patients alive at the end of
each year (or other period of time) against the units
of time. The numbers surviving may be plotted
either as absolute numbers or more commonly as per¬
centages of the original total treated, in order to
TABLE V


















































Table V. Percentage Survivors at 2nd of each Year
after Diagnosis, of Patient3 with. Cancer of Rectum
treated by combined Abdominoperineal Excision.
(Data taken from Graphs of Dukes (1944) and only
approximate.)
A,B,G.,Cp * Stages of extent of spread of cancer*
at time of diagnosis and treat¬
ment.
D = Cases unsuitable for radical excision
and treated by palliative
colostomy.
Control = Control population of same age and
sex distribution as cancer
patients.
FIGURE 4.
jgure 4. Percentage Survivors of Cancer of
Rectum at the Bnd of Bach Year after Diagnosis
(Duke's data),
A,B,C,,C~ = Extent of 3pread Stage at time of1 diagnosis,
D = Cases unsuitable for radical
surgery and treated by
palliative colostomy.
0 « Control population of same age and
sex distribution.
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be able to compare series.
In Table Y ana Figure 4 are presented the data
of Dukes as an example.
If the survivor curves of several series of
\
cancer patients are plotted as percentages on the
same scale then the area beneath each curve is
proportional to the average number of years lived
by the individuals in each series in the follow up
* )
period. We can thus quickly see the relative merits
of two forms of treatment or compare the treated with
a control non-cancer population or a control un¬
treated cancer population.
In Figure 5 are shown five 3uch survivor
curves
I. Control population of non-cancer patient3.
II. All operable cancers of the rectum, Stages
A, B, 0lt C2. (Dukes 1944).
III. All cancers of the rectum coming to
hospital. (Dukes 1944).
IV, The curve of 887 patients with cancer of
the rectum who for some reason were not
treated. (Greenwood 1926). Time is
recorded from onset of symptoms in this
curve.
Y. Inoperable cancers of the rectum, Stage
D. (Dukes 1944).
FIGURE 5*
Figure 5. Percentage Survivors of various Classes
of Rectal Cancer Patients at the End of Each Year
after Diagnosis.
I. = Control population.
II. = All operable rectal cancers, (Dukes 1944).
III. » All rectal cancers coming to hospital,
(Dukes 1944).
IV. » Untreated rectal cancers, (Greenwood 1926).
Time is measured from onset of symptoms
in this class.
V. = Rectal cancers receiving palliative
treatment only, (Dukes 1944).
I
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Examination of these curves shows
1. The area between the third and fourth
curves gives an indication of the number of man-years
saved by the most modem treatment of cancer of the
rectum. This difference is small when compared with
the survival time of untreated cancer. let the five
year survival rate of cancer of the rectum after
treatment is claimed to be about 40$. The inspec¬
tion of this simple graph gives a much better idea
of the scanty effectiveness of treatment.
2. Inspection gives the best time at which to
assess the relative value of treatment. A new
treatment might show no superiority as measured by
the five year survival rate but at two three or four
years the proportion of survivors might be appreci-
ably and significantly higher.
3. By presenting the survivors at the end of
each year or shorter period of time on a graph we get
a form of regression line. In figure 6 are two such
survivor curves. The patients were submitted to
two different forms of treatment, A and B. If we
could estimate the mean time of survival and the
slope of each line we would be able to apply tests
of significance between the lines representing the
two treatments. The mean time of survival is
TABLE VI
NUMBER OF DEATHS IN JACH YEAR AFTER TREATMENT.
Treatment










74 7 37 24 16 9 40
/«> /<T yf
72 42 45 36 30 75
200
300
Totals 146 79 69 52 39 115 500
= 17.070 n . 5 P#Q1 = 15.09
p.ooi = 20-52
Table VI. Data shorn in Figure 6 and arranged


















~l 1 1 1 "L
12 3 4 5
TIME IN YEARS
Figure 6. Percentage .,-urvivors at the End of Each.
Year after Diagnosis in Two Imaginary Series of
Cancer Patients, Each Series being subjected to
a Different Form of Treatment.
Data as in Table VT,
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difficult to estimate because we can only guess the
time of survival of those who live more than 5 years,
(e.g. by assuming that they lived for five and one
half years). This method of analysis is therefore
not feasible.
A simple method of making use of all the
survival times is to apply *X2 test. The deaths
occurring in each year along vfith the survivors for
five years are arranged in a table, as in Table VI.
Making the assumption that there was no
difference betv/een the treatments the probability of
finding such distributions of death by chance in two
successive random samples is less than one in an
hundred. It can be concluded that treatment 3 is
better than treatment A. If it was thought that
there was a tendency to overdiagnose cancer in one
or other series and that the survivors included
cases which were not cancer at all the analysis
could be made by deaths only, and this would minimise
the effects of error in diagnosis. Although not of
such an high degree of significance the result is
still significant.
From the graph it is seen that the treatment is
most effective in prolonging life in the first three
years and it is of interest to note that the
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superiority of treatment B can be shown even at the
end of the first year Q^* test P <^*01) and becomes
increasingly significant at each successive year.
This method is superior to the five year
survival rate because it makes use of more of the
information which is available and so more clearly
defines the behaviour of each group after treatment
Its superiority in sensitivity is shown by the
failure of the five year survivor index to be signi
ficantly different in the two series when analysed
by the^" teat or the standard error of the
difference between two proportions.
Summary.
The five year survival rate as an index of the
effect of cancer treatment conceals so many fallacies
that little reliance can be placed upon it in
comparing the results of different forms of treat¬
ment .
The survivor table is better. It is simple,
applicable to all cancer types, and may indicate the
benefits of treatment, if any, long before five
years. It does not, however, indicate the factors
which influence prognosis nor does it overcome the
difficulty of assessing the malignancy of the
cancers which are being treated.
VI. A SUGGESTED INDEX OP CANCER BEHAVIOUR.
1. The Problem.
In attempting to assess the survival or
curability of a group of patients we have at least
two groups of variables.
Firstly, there is the variability of the
factors influencing the malignancy of the individual
cancers.
Secondly, there is variability in the factors
in the host which influence the reaction to a malig¬
nant tumour. Even if we could rigidly define the
.
degree of cancerousnesa of a malignant tumour all
the patients with that particular degree would not
:'V
die simultaneously.
It is possible in the second case to define
accurately the variability in survival. There is
no doubt that the individual times from diagnosis to
death can be accurately measured if the follow up is
long enough and thorough enough. Nevertheless we
might not be able to measure the influence of the
individual factors or even be aware of their exis¬
tence.
The real difficulty lies in defining the
variability in the assessment of the degree of malig¬
nancy at the time of diagnosis.
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Much might be gained in the study of cancer if
cancer were considered analogous to an infectious
disease or toxic lesion in which the advance or re¬
gression of the lesion depended on the interplay
between the virulence of the infecting organism and
the resistance of the host. Since both of these
might vary independently if we wished to find a
relationship between virulence of the organism and
time of dying, we are presented with a problem
identical with that in cancer.
Modern biological statistics have been evolved
to elucidate such complicated bacteriological and
pharmacological problems. It is regrettable that
they have never been applied to the problem of
cancer.
2. The Median Lethal Time -
Since the five year cure rate is now becoming
discredited it is necessary to evolve some simple
measure which will summarise cancer behaviour.
For illustration, the extent of spread of cane*
of the rectum found at diagnosis will be used as a
measure of the inherent malignancy of the tumour,
without considering the period of time for which the
tumour has been growing. Other attributes of the
FIGURE 7
Figure 7. Cumulative Percentage of Deaths of
Reetal Cancer Patients at the End of Each Year
after Diagnosis.
Simple Time Scale.
A,B,ClfC2,D, - as in Figure 4.
host or cancer will "be ignored in the meantime.
For reasons to he given later, it is more
convenient to plot, not the number of survivors, hut
the number of deaths in cumulative fashion. In
Figure 7 are recorded the cumulative percentage of
deaths at the end of each year after diagnosis of
patients with rectal cancers which were in Stages A,
B, C^, C2 and D, at the time of diagnosis. (J) =
most extensive stage = unsuitable for radical
surgery.)
According to the assumption made,these curves
show the rates of dying of groups of patients, each
member of the group having a cancer of roughly the
same degree of "caneerousness". In the less malig-
nant groups the final deaths occur well beyond the
limits of feasible follow up. In these the upper
limit of survival may be unk»i07m, and it is not
possible to calculate accurately the mean period of
survival or the standard deviation. Under such
circumstances we can summarise our data by another
average in place of the mean - namely the median.
In the Figure an horizontal line at the level
of the 5©# death point has been drawn, and the median
lethal time can easily be read off. It is not
necessary to draw a graph but a visual representation
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is useful in showing any sudden alteration in the
rate of dying which might have significance. An
improved form of treatment will lead to a "shift to
the right" of the death curve with increase in the
median lethal time.
The Advantages of the T.h.I. these are:-
1. The first 50$ of deaths occur within a
relatively short time of diagnosis and accurate long
term follow up is of less importance.
2. A patient who dies is more easily counted
than a patient who survives for an indefinite period,
3. If the patient dies within one or two
years it will he easier to establish whether he did
die of cancer, or of an unrelated disease.
4. At cancer sites such as the breast and
prostate, overdiagnosis of cancer is the rule. In
the death curve, since the slope of the curve is
steepest round about the 50$ death point, inclusion
of a few patients who did not have cancer and who
survive for a long period will only result in a
relatively small increase in the median lethal time
of the group. But their inclusion would consider¬
ably increase the five year survival rate or the
mean survival time of the group.
5. In the division of a aeries of cancer
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patients into sub-groups, clinical and histological
criteria are so vague that borderline cases occur in
which opinions may Justifiably differ.
The patient who is placed in a group of a
higher grade of malignancy than is correct will, on
the whole, die later than the other members of the
group into which he is placed. then the cumulative
death curve is plotted, the majority of those
patients incorrectly included will die among the
latter 50$ of the cases and will not affect -the 50$
death point to any extent. The reasoning is the
same as under para. 4.
5. If a more effective method of treatment
were applied one would expect it to be most obvious,
not in those who would live a short time nor a long
time, but in the intermediate lengths of survival.
Even a 3M£ll increase in the true average survival
time would shift the curve significantly to the
right.
We are, in fact, measuring principally the rate
of dying of the more rapidly dying half of any group.
By using the median lethal time as an index of
survival or curability, the grosser errors of the
five year survival rate are avoided. This index,
in fact, takes much less trouble to compile than the
- 73 -
five year survival rate. It is easily comprehended.
Heed for a Measure of Variability. I'he
principal disadvantage of a proportional index is
that a proportion shows such wide variability in
random sampling from the same population. If we
replace this by an average, namely the median, we
must define the expected variability to be found in
this average when different samples are drawn from
the same population.
As a measure of the dispersion round the
median value, we could calculate the quartile devia¬
tion Q, where Q = and Q3 and Q1 are the upper
and lower quartiles of the sample. But this value
cannot be extended to further statistical treatment
and a similar objection is made by statisticians to
the standard error of the median.
It is therefore necessary for the definition
of variability round the average value to translate
the median value into some other statistic which
would be more suitable for the calculation of its
error and more intricate analysis.
3. Suggested Method of Analysis.
In any experiment designed to estimate drug
toxicity, it is found that individual animals show
considerable variation in the time of exposure to a
18
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fixed dose of the drug before death occurs. If
groups of animals are given increasing doses of the
drug then it is found, as one would expect, that th
higher the dose the sooner, on the average, the
|
animals in that group die.
With, any particular dose, when the cumulative
death - time curve is plotted it is found to be of
sigmoid shape, which becomes more symmetrical if
time is plotted on a logarithmic scale. When the
'
frequency distribution is plotted against logarithmic
time scale it has been found that this latter curve
is approximately of the "normal" symmetrical type,
and for practical purposes is assumed to be so.
That is, the frequencies of individual times of dying
are found to be normally distributed provided time is
.
recorded on a logarithmic scale. It follows-from
this that the median lethal log. time and the mean
lethal log. time are the same.
It is always much easier to grasp the importance
of a relationship between two factors if their re¬
lationship can be expressed as a straight line on a
graph. Assuming that a frequency distribution curve
is normal, the abscissa can be measured in units of
the standard deviation (S.D.) of the distribution -
plus or minus from the mean value - that is, in
FIGURE 9
Figure 9. Prohit Transformations of Percentage
Deaths of Rectal Cancer Patients.
Logarithmic rime Scale.




Figure 8. Cumulative Percentage of Deaths of
Rectal Cancer Patients at the Snd of Bach Tear
after Diagnosis.
Logarithmic Time Scale.
Data as in Figure 4.
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"standard measure". An ordinate raised at a point
corresponding to any particular value of S.B.
measured along the abscissa plus or minus from the
mean, will cut off an area to the left of the
ordinate which is a constant percentage of the total
area under the curve, provided it is of "normal" type
If we plot the standard deviate corresponding to the
proportion which have died by a particular time,
against the logarithm of that time, then the points
obtained should lie on a straight line. (In order
to avoid the use of negative deviates it is now
customary to add 5 to the normal deviate and obtain
the "probit" value.)
In this particular case, dosage is the con¬
trolled variable.
The time-cumulative mortality curves of our
subgroups of rectal cancer patients are, in fact,
sigmoid curves. The curves are again more symmetri¬
cal if the time is measured on a logarithmic scale -
Figure 8. The probit transformation of these
distributions results in relatively straight lines »
Figure 9. The hypothesis can be put forward that -
The Frequencies of the Logarithms of the Times of
Survival after Diagnosis of Individual Patients
bearing Cancers of the Same Degree of malignancy are
normally Distributed.
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The hypothesis is applied empirically as a
convenient method of analysing the data but there is
no reason why the data should necessarily conform to
it. It may be that some other method of relating
time to number of deaths might give a more symmetri¬
cal "normal" distribution.
The groups of human animals behave as if they
had been injected with different doses of that drug
called "cancerousness" which has a long continued
slow-acting but nevertheless frequently ultimately
lethal effect.
Fitting the Regression Line. The Estimation
of the Mean and Standard Deviation. Calculation of
Standard Error of Mean.
If all or nearly all the patients of the Stage
died, the procedure for fitting the regression line
would be as follows
1. The individual times of dying would be
recorded and ranked in order of time of death.
2. Since in cancer statistics the numbers are
usually large, it will be necessary to "group" the
individuals into 10 to 20 subdivisions for easiness
of handling. (If the number is less than 30 or so
the individual times of dying wouia be conveniently
used.) The class interval (time) should be chosen
on the logarithmic scale for ease of computation
later, that is, the original times up to which deat
are recorded should he in geometric progression -
1 week, 2 weeks, -4,-8,-16,-32 weeks etc.
3» The cumulative distribution up to the end
of each interval is then calculated and converted to
a percentage of the total distribution.
4. The standard deviates or probits corres¬
ponding to these percentages are obtained from
statistical tables (e.g. Fisher & Yates Table IX)
and these probits are plotted against the upper
limits of the corresponding class intervals.
5. The best fitting line through these points
can be drawn by inspection. Any systematic devia¬
tion of a group of points from the line representing
the major portion of the distribution can be seen.
Such systematic deviation is most likely to occur at
either or both ends of the distribution. (This will
be discussed later.)
6. If the distribution is normal that is, if
most of the points lie close to the line, then an
estimate of the mean Clog*) time of dying can be made
by finding the point at which, the regression line
cuts the ordinate for 5 probits (= 50 ' deaths). An
estimate of the standard deviation (S.D.) of the
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distribution can also "be found and this will be that
period of time (in log, units) measured along the
abscissa which corresponds to 1 probit (= 1 S.D.).
The slope of the line will then be where the
ordinate is measured in probits and 53.3). is
measured in log. units. In cancer data with its
large numbers, this graphical estimate of the mean
log. time and standard deviation (in log. units) will
be reasonably accurate for the calculation of the
standard error of the mean and for application of
tests of significance.
The mean and standard deviation can be converted
back into the simple time scale e.g. in weeks.
7. The graphical estimates of the mean log.
time and its standard deviation can be checked by
calculating from the original data (Bli3S 1937).
As far as can be ascertained Boag (1948) was
the first to suggest the use of the log. time-
mortality distribution in cancer statistics. This
work has been unfortunately ignored probably because
the method of application suggested by him was too
complicated for clinical use. It is felt that his
attempt to predict the percentage of "cures'* at a
fixed time after diagnosis, and to use this as an
index, introduces unnecessary difficulties.
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■lie&ression Lines: (Incomplete distributions).
Only rarely will the times of dying of all the
patients in each stage he available for calculation
and even if they were, they may not be considered
suitable for inclusion in the calculations.
1. Apart from the more malignant stages of
most tumour types, the period of feasible follow up
>
is not long enough to include all possible deaths.
2. The plotted points commonly lie on a
fairly straight line until the upper end of the
distribution, where they "tail off" and deaths occur
less frequently than expected, - 3ee Figures 9 & 14.
The explanation is as follows.
In animal experiments every animal in the group
receives the same dose. But in human material all
the patients in each stage do not have cancers of
exactly the same degree of malignancy. We are, in
fac^, recording the distribution of times of dying
of patients who might bear a tumour of one of a range
of degrees of malignancy. Each degree of malignancy
would have its own distribution of deaths. The
frequency distributions (normal) of times of dying
of groups of patients with three closely related
degrees of malignancy can be represented in Figure
10A and the probit transformations in Figure IOC.
FIGURE 10
ifaure 10. Distributions of times of Deaths after
Diagnosis of Groups of Patients bearing Cancers of
three closely related Degrees of lialignancy. and
Combined Distribution of Times of Deaths of all
Patients.
Thin Lines » three constituent distributions.
Thick Line * combined distribution.
a. « frequency distributions.
b. = cumulative percentage distributions.
~ proMt transformation of distributions.
Logarithmic Time Scale.
(NOTE: Scale of ordinate different in each Graph.)
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(It is assumed that the three distributions have
equal numbers and the same S.D.) '/hen the times of
dying of all the individuals in all the series are
presented as a single frequency distribution, the
resulting distribution is one with its hump
flattened. then this combined distribution is
transformed it takes the form of a curve of reversed
sigmoid shape which runs first to the more malignant
side of the central distribution then crosses over
it at the 50^ death level, and then turns again and
runs on the less malignant side of the central degree
slowly converging to the line of the lea3t malignant
degree•
Owing to the crudeness of our method of assess¬
ing malignancy, the stage distributions in practice
will include cancers of different degrees of malig¬
nancy and will therefore rarely be strictly "normal".
The points at which, and the acuteness with which,
the "cross over" occurs will depend on the relative
numbers in each distribution and ho?/ widely divergent
the means of the individual distributions are.
Provided the majority of patients have cancers of
uniform malignancy then the "cross over" will occur
beyond the mean lethal time which will be little
affected in the graphical estimate of the mean.
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(With a range of malignancies which lie close to¬
gether, if each malignancy is represented by the
appropriate number of patients then the combined
distribution may be approximately normal in type
and the probit line becomes almost entirely "cross
over". The combined distribution of Stages A, B,
Cp & C2 of rectal cancer patients - "total"
distribution in Table Y - is approximately normal
and transformation produces a nearly straight line.)
(Minor degrees of a reversed sigmoid type of
curve in a cumulative log. tine distribution curve
are not uncommonly obtained with experimental animals
which have all received the same dose of drug. This
is due to inclusion of subgroups of animals which
have similar genetic constitution.)
5. 'ie have assumed that if we followed our
patients long enough the distributions would be
completed and all the patients die of canoer. At
the less malignant degrees of some cancer sites
however, some patients would live to die a non-
cancer death. Cases of neoplastic growth that are
histologically on the border line of "malignancy"
may or may not metastasise during the natural terra
of life. But those that died of cancer would




As in animal experiments, a dose may not be large
enough to kill all the animals but those that do die
have survival times which form the lower end of a
normal distribution.
Accordingly, for practical or natural reasons,
the distributions will be "truncated". The proce-
dure for obtaining the best fitting line to represent
these distributions is similar to that given previ¬
ously. "he difference is that a provisional line
is drawn first through those points which are
distributed normally. Those points (if any) at the
upper end which deviate systematically from this
|
distribution are discarded and a regression line
through the remaining suitable points is fitted by
eye or by calculation.
i '
The estimates of the mean and standard deviation
are obtained as before from the graph. These will
not be as accurate of course, as those calculated
from the entire distribution.
For this reason when tests of significance are
applied the standard error of the mean (log.) has to
be corrected by multiplying it by a constant, the
value of which depends on the point at which the
distribution has been truncated. This constant E
can be obtained from Table YIII of Bliss, (1937).
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Tiie greater the degree of truncation the less
accurate is the standard deviation from the graph,
and the greater the constant E must he to increase
!
the estimate of standard error of the mean. Pro¬
vided the truncated portion of the distribution is
not more than 25$ of the total observations, then
the correction factor is so close to 1 that for
!
ordinary medical purposes the uncorrected estimate
of the standard error is probably adequate.
In cancer treatment the distributions might
also be irregular at the lower end since operative
interference might result in premature deaths. In
fitting the regression line, it might be advisable
to ignore that part of the line formed by the points
representing the deaths in, say, the first 2 or 4
weeks. Even if most of the distribution is avail-
i
I
able, it would generally be wiser to use that portion
of the curve representing between 16$ - 84$ of the
deaths, i.e. between - 1 S.D. and +> 1 S.P., or
between 4 and 6 prcbits. (Operative deaths however
must be included in the figures for the numerator and
denominator in calculating percentage deaths.)
f '
Test of Significance. By using the methods
outlined above, it is possible for tests of signifi-
| • . ' f t
cance to be applied and the number of patients re¬
quired to show one distribution or regression line
FIGURE 11.













Figure 11. Probit Transformation of distribution
of Deaths of a Group of Untreated Cancer Patients:
and Distributions of the Same Patients after the
Time of Survival of :.ach Patient has been increased
in certain Proportions.
Logarithmic Time Scale.
A = Original distribution.
B « Distribution after prolongation of the life
of each patient by a constant time irres¬
pective of time of survival without
treatment.
C = Distribution after prolongation of each life
by a constant logarithmic time irrespec¬
tive of time of survival without
treatment.
D « Distribution after prolongation of each life
by a constant proportion of the logarith¬
mic time of survival without treatment.
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as being significantly different from another is
much less than if the index of cure were the five
year survival rate.
If a new form of treatment were "better than
those now current, it might prolong the life of each
patient in any one of at least four ways.
1. By a constant time irrespective of the
natural time of survival without treatment.
2a. By a constant proportion of the absolute
time he would have survived without treatment, or
what is the same
I
2b. by a constant log. time irrespective of
I ' ■
time of survival without treatment.
3. By a constant proportion of the logarithm
I '
of the time he ?/ould have survived without treatment.
The theoretical distributions of times of dying
and the probit transformations of a population whose
individual survival times were increased by each of
these three methods is shown in Figure 11.
Improved treatment will ba shown by a shift of
the site of the line to the right and possibly by a
change in its slope. It is most likely that method
two will, in fact, be the one found to result-
increase in the mean lethal time with no change in
the standard deviation. The line of the distribution
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of deaths after improved treatment will then he
parallel to the line of distribution of deaths after
the old treatment.
'
4. The Extension of the Method to make use of
Other Factors.
The ITse of other Attributes. So far, extent
of spread at diagnosis has been used as the most
accurate single criterion of degree of malignancy
in the rectum. But there are other sites, e.g.
thyroid, in frfiich measurement of extent of spread is
not possible - at least it is not easy to classify
tumours into stages. It would then be necessary to
fall back on some other attribute; in the case of
the thyroid the histological pattern is generally
a fair guide to prognosis and length of survival.
Use of Multiple Attributes. There is no need
to confine ourselves to one attribute - in fact it is
undesirable since we are ignoring useful information
which might help to predict cancer behaviour more
clearly. Any characteristic of the tumour or the
patient which can be measured however crudely should
be noted.
#e can thus define a subgroup by two or more
attributes. Bach of our "extent of spread'1 stages
of rectal cancer could be subdivided into four
FIG-MS 12











Figure 12. Diminution of Standard aviation of
Distribution by us© of s Second Attribute to
classify Cancer Patients
Thick Lines * Distribution of deaths of extent of
spread stages A,B,C, and B» of
cancer at some site.
Thin Lines « Distribution of deaths of subclasses
resulting from division of each
extent of spread stage group into
four subgroups which are classi¬
fied by histological grade I, XI,
III or IV.
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subgroups, each, subgroup classified by an histologi¬
cal grade of malignancy. (It would have been better
if histological grading had been divided into 3 or 5
grades.) We would then have 20 subgroups in place
of 5 main groups.
The linear transformations of each of these
I
subgroups can then be plotted and provided histologi¬
cal grade of malignancy is associated wit . , rognosis
we should get straighter lines than those of the
main groups. (Pokes (1940) claims that such an
association exists.) It has been pointed out be¬
fore, that the slope of the line formed from a
distribution which is the sum of several smaller
closely related but slightly dissimilar distributions
is always less than each of the individual distribu¬
tions. That is, the variance of the summed
distribution is probably always greater than the
variance of any one constituent distribution. This
can be shown graphically in Figure 12. The thick
lines represent the probit transformation of disfcri-
butions of times of dying or extent of spread stages
of an imaginary series of cancer patients. The thin
I
lines represent the distributions of the subgroups
into which these main groups might have been divided
by the use of histological grading. Prognosis of an
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individual case can "be more accurately predicted by
the use of the second attribute. Using only extent
of spread a3 our criterion we might say that the mean
lethal log. time in years of all Stage C cancers is
0.24 and the standard deviation is 0.39. But for a
cancer of Stage C with an histological pattern Grade
III the mean lethal log. time is 0.19 and the stan¬
dard deviation is 0.32. The subgroups could again
be subdivided a second time by a third attribute.
Provided each characteristic of the tumour is
associated with malignancy and killing power the more
attributes by which the tumour is classified the more
nearly vertical becomes the probit transformation of
the distribution of each subgroup of tumours which
have the same characteristics. That i3 the standard
deviation diminishes. The characteristics of the
patient as well should be used e.g. sex, age, state
of nutrition, site of tumour, time from first symptom
i
to treatment, etc.
The significance of each factor in influencing
the time of survival can be calculated mathematically.
Squally important tests of significance can be applied
between one series of patients and another by the use
of the multiple regression equations,and the calcula¬
tion of the standard error of the estimate of the
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mean of tii© regression lines of the two series.
This is a problem of considerable mathematical
complexity.
It II
A very much simpler method is to perform a t
test using the means of each subgroup. The means
are arranged in a two way table and the probability
of finding by chance such differences between the
mean values for each subgroup in the two series can
!
be calculated and the significance of such differences
can be assessed.
5. Some Difficulties.
If a form of treatment were introduced which
absolutely "cured" some patients and had no effect
on others, then those that died might not necessarily
form part of a "normal" distribution and the method
suggested here would not be applicable. Such a
'
treatment however, would almost certainly prolong the
life of those not "cured" and the distribution would
then become a "biologically truncated" normal distri¬
bution. If a "curative" treatment were introduced
it would be obviously so and there would be no need
■
for statistical analysis to prove it. (Compare
penicillin in pneumonia with the serum treatment of
pneumonia.)
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If patients who do not have cancer at all are
included among those labelled "cancer" we may get a
distribution of deaths which is not normal. It is
often difficult to make the diagnosis or exclude the
diagnosis of cancer merely by histological examina¬
tion of the excised organ. Overdiagnosis of
prostatic carcinoma, even by the most experienced
surgical pathologist, probably accounts for 5 - 10$
of the total cases labelled prostatic carcinoma.
The time distribution of deaths of the supposed
cancer patients will be a combination of the two
widely differing distributions, that of patients with
cancer and that of patients with simple prostatic
hyperplasia. If the latter form an appreciable
proportion of the total, then the probit transforma¬
tion results in a curve which is far from a straight
line (as curve B in Figure 15). The patients who
die of cancer may in themselves form part of a normal
distribution but the denominator of the proportion
from vfhich the probit percentages are derived is
larger than it should be.
The Use of the Mode. One possible way out of
the difficulty is to use the mode as the average
measure in place of the mean or the median. In a








Us© of Modal Time of Dying to estimate
er of "True'1 Cancer Patients in a Series
of Patients labelled Prostatic Carcinoma but
actually containing an Unknown Number of Non-
Cancer Patients.
Logarithmic Time Scale.
A » Frequency distribution of times of dying
of "true" cancer patients.
B = Frequency distribution of times of dying
of non-cancer patients.
C = Frequency distribution of times of dying
of a series of patients of which 80 *
were "trueM cancer patients and 20 '
were non-cancer patients.
All three distributions contain equal numbers.
If we plot a frequency polygon with the
abscissa measured in log. time units then the mid¬
point of the interval of time in which the greatest
number of deaths occurs will be an estimate of the
modal log. time of dying of the cancer patients
(» mean log. time theoretically). The accuracy of
this estimate will depend on the size of the sample
and the fineness of the grouping the data will per¬
mit. The two individual distributions of dying -
"true" cancer patients and non cancer patients - can
be represented in Figure 13. The distribution in
the heavy black line 3hows a distribution composed
of 80^ of cancer patients and 20$ of non-cancer
i
patients. The modal log. time of dying of the
combined distributions differs little from the mean
log. time of the true cancer patients. That part of
i
.
the curve lying to the left of the modal time will
then represent roughly the lower half of the distri¬
bution of wtruen cancers. A probit transformation
of the lower part of the distribution of true cancers
can be constructed and estimates of the mean and
standard deviation obtained.
It may be that the crude modal lethal time would
be difficult to calculate because the number of
patients is small and the grouping coarse. Possible
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solutions of the difficulty are;-
1. Assuming we are dealing with the lower
half or two thirds of a normal distribution it is
possible to calculate the constants of the distribu¬
tion (mean and standard deviation) even although the
i
number of individuals in the truncated portion is
unknown. The mathematical calculations involved
require professional mathematical skill.
2. A reasonably accurate solution could
probably be obtained graphically. A frequency
polygon is constructed and an estimate of the mode,
i however crude, is made.
The number of deaths lying to the left of the
mode is doubled and taken as the total "true" cancer
.
patients. The probit transformation of the distri-
bution of deaths is calculated with this number as
the denominator for calculation of the proportion of
deaths up to the end of each time interval,and a
provisional curve drawn up. If this is not a
reasonably straight line then the denominator is
increased or diminished by, say 10' and a further
provisional curve obtained; continue to vary the
denominator for the calculation of the percentage
dying, until the points of the probit distribution
lie with lower half or 2/3rds of the distribution as
FIGURE 14
TIME IN YEARS
Figure 14. Probit Transformations of Distributions
of Deaths of Patients with Untreated Cancer at
various Sites, Greenwood's Data (1926).
x——X * Cancer of Breast.
— /N. — Cancer of Reetua.
©— O as Cancer of Cervix.
□'— D = Cancer of Stomach.
4 +" - Cancer of Oesophagus
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close to a straight line as possible. This is
assumed to be the distribution of the "true" cancer
patients. (The final approximations can be calcu¬
lated by rather complicated formulae, see Stevens in
Appendix to Blias, 1S3T.)
'The U3e of the provisional estimate of mode
depends on the assumption that the two distributions,
cancer and non-cancer are significantly far apart.
If, however, no method of staging the cancer into
even crude degrees of malignancy is available, and
if a wide range of degrees of malignancy exists in
the particular tumour type, then it may be that the
non-cancer patients cannot be separated, since the
combined distribution of deaths of cancer and non-
cancer might be approximately normal.
.
6. hack of Proof of Cure.
In Figure 14 are seen the linear transformations
of distributions of times of dying of patients with
cancer at several sites who were not subjected to
treatment (Greenwood, 1926). The Figure is included
to show that the survivors (untreated) for five years
of those cancer types which are claimed to be
"curable" if "caught in time" - breast, rectum -
merely represent the tail end of a distribution whose
pattern could have been predicted with an high degree
of accuracy at the end of the first year after
diagnosis. In the less malignant groups of cancers
at these sites, even when untreated, the proportion
of the distribution lying to the right of the five
year ordinate would be expected to be much greater
merely as the result of chance variability in
behaviour.
A substantial proportion of the patients who
bear the less malignant cancers and who survive for
five years after treatment would have survived for
five years -without it. It is suggested that most
of the so-called "cures" resulting from treatment are
contributed by this proportion.
.'e have suggested earlier that the principal
factor influencing survival after treatment is the
inherent malignancy or "cancerousness" of the tumour.
A study of these regression lines supports the argu¬
ment that treatment is merely palliative.
■
Suppose there are 100 cancers of Stage CI at the
start. 41 of these survive for five years and will
be claimed as "cured". This number should represent
1. those patients whose cancer has been successfully
removed, less a small number who have died a non-
cancer death in the first five years; 2■ those odd
TABLE VII.






























0.5 4 2 1 0 2
1 24 14 • 2 1 15
2 57 32 4 2 34
3 79 45 6 3 48
4 89 51 8 4 55
5 95 54 11 5 59
6 97 55 14 6 | 61
7 99 56 17 7 63
Table VII. lumber of Deaths expected to occur by
the End of each Year in 100 Cancer Patients with
Stage Cancer of Rectum.
Figures are based on the assumption that 57
"unaured" cancer patients should behave like
untreated cancer patients (as in Figure 15) and
43 "cured" patients should behave like a
control population which did not have cancer.
FIGURE 15.
TIME IN YEARS
Figure 15. frobit Transformation of Expected
Distribution of Deaths of Stage 01 Cancers of
Kectum if Cancer were "Curable".
Logarithmic lime Scale.
A = Distribution of untreated rectal cancer
patients.
B * Distribution of deaths of an imaginary
series of Ci rectal cancer patients,
of which 57? were "uncured" and behaved
like untreated rectal cancer patients
and 43$ were "cured" and behaved like
controls. Data as in Table VII.
C, = Distribution of deaths of 0, cancer
patients, as actually observed.
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patients in w&om treatment has failed hut who have
just managed to survive beyond the five year limit.
Assume therefore there are 57 patients in whom treat¬
ment has failed and -who will behave like untreated
cancer patients. The remaining 43 will behave like
a control population who have not got cancer at all.
If this were 30 then deaths should occur in the 100
patients as in Table VII. /hen these figures are
plotted either as a log. time-cumulative frequency
distribution or as a linear transformation, the
!•
distribution of deaths is not normal. In the latter
case the line is a curve with diminishing gradient
after a sharp initial rise (Figure 15). The line
"tails off" for the reasons given in a previous
section but in this case the two populations (cured
and uncured) have widely divergent means and not
closely related as before.
Since the members of this imaginary series are
not dying off according to the expected behaviour of
untreated cancer, then the diminishing gradient, i.e.
diminished rate of dying, could justifiably be
ascribed to treatment. (The probit lines of
Greenwood's untreated cancers and Duke's Stage C-T
.
cancers are given for comparison.)
In actual fact, none of the lines representing
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stage groups of rectal cancer patients does "flatten
out" to this extent (at least not the most malignant
groups). Each group forms a sample of a normally
distributed population still "normally distributed"
even after treatment. Treatment appears to prolong
life by only a small proportion (not necessarily
j arithmetic) of the tiro patients would have survived
without treatment.
The great attraction of dividing cancers into
stages is that it allows the surgeon or radiothera¬
pist to deceive himself into believing that he has
achieved a high rate of success in at least some
group of cancers, - the least malignant ones.
7. Checking the Consistency of the Diagnoses.
A study of the total distribution of deaths
! .
,
after diagnosis and treatment at any site shows that
these distributions are of normal type. It has also
been shown earlier that the distribution of deaths at
each degree of malignancy was also normal. The only
way in which these conditions can arise is when the
numbers of the individuals constituting each degree
of malignancy are also normally distributed. Se are
therefore entitled to propose the general law that:-
"At any site the frequencies of occurrence of cancers
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at the individual degrees of malignancy are normally
distributed."
If we wish to test the accuracy of diagnosis in
a series of cancer patients which is presented after
having been submitted to a new form of treatment
there are at least two methods.
1. The distribution of deaths from the whole
series is plotted (including untreated cases). If
the mean and standard deviation derived from the lower
half of the distribution do not show a significant
difference from those of previous forms of treatment
then any superiority claimed is likely to be due to
inclusion of cases which were not malignant or of a
greater proportion of cases which were of a lower
degree of malignancy than the average. This will be
confirmed if the line wfall3 away" and takes the form
of the line B in Figure 15. The more closely the
points of the distribution fit a straight line the
more accurate is the diagnosis likely to be.
hen the distributions at each stage or degree
are then contrasted, if the differences are only ob¬
served in the least malignant degree or degrees, then
it is almost certain that the standard of diagnosis
was not the same in the two series.
2. /hen a series of cancers are divided by
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"stages" or by some other assessment of degree of
malignancy then the numbers in each stage group
should be such that the central degrees of malignancy
contain an higher proportion of the total than either
the higher or lower degrees of malignancy, i.e. that
the numbers in the degrees be roughly normally dis¬
tributed. If the least malignant degree of the test
series contains an higher proportion of cases than
the control series then any apparent superiority of
treatment in the test series is likely to be due to
the preponderance of cancers of lower degree. We
could perform test on the numbers in each group
of the two series and find if they were likely to
have been drawn from the same population. If there
is a significant difference then there has probably
been bias in the allocation of the cases.
A claim for an increase in the overall cure rate
of cancer at some site should be viewed with sus¬
picion if the proportion of "early" cancers in the
lower degrees of malignancy in the series presented
is greater than is usually found.
These tests assume that in any geographical
area of reasonable size in Great Britain the cancers
which occur at a \;ne site are not, as a group,
likely to differ materially with respect to age,
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duration of symptoms, etc., at the time of diagnosis
from those occurring in adjacent areas.
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VII. DISCUSSION and SUMMARY.
It is generally realised that the five years
survival rate is not a satisfactory measure of the
value of oancer treatment but it continues to be
used because there is thought to be nothing better.
The treatment of cancer, especially by radio¬
therapy, is expensive, yet at few cancer sites is
there general agreement as to what is the best form
of treatment. Present methods of treating cancer
are the same as they were 25 years ago. If present
methods of analysing the end results of treatment
have not shown one or other form of treatment to be
the best, then either the methods of analysis are
inadequate or all treatments are equally effective
or ineffective.
It is surprising that the World Health
Organisation Sub-Committee on Registration of Cases
of Cancer should report - "(a) The absence of any
commonly agreed method of calculating survival and
apparent recovery ("cure") rates for cancer leads to
great confusion and prevents correct comparisons of
the results of different therapeutic procedures."
and then recommend that the method usually used at
present - percentage survival at the end of each
year - is the method of choice. Admittedly, the
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details of the method suggested are clearly defined
"but essentially similar and probably equally
efficient methods have been in use in many centres
for years without diminution of the "confusion" in
these centres.
It is not appreciated that the principal source
of the "confusion" is, not in the method of analysis
of the figures themselves, but what is included in
the counting. Surgeons and radiotherapists do not
realise, or ignore, that the diagnosis of cancer at
the time when the diagnosis is made, is merely
skilled guessing. There is little doubt that most,
if not all "better" treatments, depend for their
apparent superiority on the employment of an histolo-
gist with less rigid criteria of malignancy than the
average, or on the failure to employ an histologist
at all.
On reading elaborate collections of the end
results of cancer treatment, one gets the impression
that the editors believe that if they could get sore
and more series of five year survival rates then they
would get closer to the truth and be able to prove
that this or that treatment is best. This is
unlikely. In each series we do not know the number
of wrongly diagnosed cases and the relative
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malignancies of the individual cancers. Since in
cancer there is a bias to overdiagnosis, the errors
in clinical or histological judgment do not cancel
one another out and comparisons between the averages
of groups of series are not likely to be much more
valid than between individual series.
The source of all the fallacies is that today
we have no accurate single measure of the degree of
"eancarousness11 of any neoplasm at the time of
diagnosis. In order to minimise the effects of
errors in diagnosis it is suggested firstly that,
paradoxically, the numbers dying should be the basis
of our index of "curability" since if the patient
dies of cancer there is little doubt the diagnosis
was eorrectj secondly, since our measure of caacer-
ousness is so crude, we should direct our attention
in each group of patients with cancers which we be¬
lieve to be of the same stage or degree of malignancy,
to that half or portion of the group which dies most
rapidly. These patients presumably bear a high
proportion of the more malignant tumours of that
stage or degree and their tumours are accordingly
more uniform in their "cancerouaness".
It is suggested that, for everyday clinical use,
the Median Lethal Time after diagnosis is a simplex
- 102 -
and more accurate index than the fire year survival
rate.
It has been postulated and is generally
demonstrable that, if time is recorded on a logarith¬
mic scale, then the frequencies of the times of
survival after diagnosis of individual patients with
cancers of the same degree of malignancy are normally
distributed. We find that the more rapidly dying
half or two thirds of our patients in each stage form
the lower part of an approximately normal distribu¬
tion. Since the distribution of deaths is assumed
"normal" then theoretically, the median = the mode =
the mean. If we obtain an estimate of the mean log.
■
time and its standard deviation, the distribution of
our times of dying is defined and it is possible to
apply tests of significance for differences between
comparable series. Under certain circumstances it
might be more accurate to employ the mode and assume
this equals the mean.
A statistician could determine an accurate
estimate of the mean log. time of survival for a
particular stage or type of cancer. Experience
would show that unless a new form of treatment in¬
creased the median lethal time by a certain proportion
of the standard for the region, then further
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mathematical analysis would be unlikely to show the
difference as significant.
By extension of this method to include the
3tudy of the influence of multiple characteristics
in either the patient or the tumour an intricate
system of analysis can bo built up. Although for
full accuracy the mathematical procedure of the
analysis of variance is complex, fairly accurate
results can be obtained by simple graphical methods
The methods outlined here were intended to be
applied to the study of the behaviour of human cancer
in the hope of accurately measuring the importance of
any factor, in the tumour or the host, which might
influence the period of survival. The measurement
of the possible influence of treatment has here been
given pride of place but the methods need not be
confined to the analysis of this factor alone. It
is likely that treatment does not greatly influence
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